

F6

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/080578 A1(51) International Patent Classification⁷: **C07D 215/38, 215/40, 217/22, 217/24, 217/26, 237/28, 401/12, 401/14, 521/00, A61K 31/4709, 31/472, 31/4725, 31/501, 31/506, A61P 29/00**

(GB). MOYES, Christopher, Richard [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). ROGERS, Lauren [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(21) International Application Number: PCT/GB03/01302

(74) Agent: HORGAN, James, Michael, Frederic; European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English


(30) Priority Data:
0206876.5 22 March 2002 (22.03.2002) GB(71) Applicant (*for all designated States except US*): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).(72) Inventors; and
(75) Inventors/Applicants (*for US only*): BROWN, Rebecca, Elizabeth [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). DOUGHTY, Victoria, Alexandra [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). HOLLINGWORTH, Gregory, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). JONES, A., Brian [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). LINDON, Matthew, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN

WO 03/080578 A1(57) Abstract: The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R¹, R², R³, R⁴, R⁵ and R⁶ are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.

PATENT COOPERATION TREATY

PCT

REC'D 08 JUL 2003

WIPO PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference T1566	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/GB 03/01302	International filing date (day/month/year) 21/03/2003	(Earliest) Priority Date (day/month/year) 22/03/2002
Applicant MERCK SHARP & DOHME LIMITED		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 10 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :
 - contained in the international application in written form.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority in written form.
 - furnished subsequently to this Authority in computer readable form.
 - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. Certain claims were found unsearchable (See Box I).

3. Unity of invention is lacking (see Box II).

4. With regard to the title,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

HETEROROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN

5. With regard to the abstract,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

HETEROROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN

The present invention is concerned with heteroaromatic ureas and
5 pharmaceutically acceptable salts and prodrugs thereof which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

The pharmacologically active ingredient of chilli peppers has been
10 recognised for some time to be the phenolic amide capsaicin. The application of capsaicin to mucous membranes or when injected intradermally, causes intense burning-like pain in humans. The beneficial effects of topical administration of capsaicin as an analgesic is also well established. However, understanding of the underlying molecular pharmacology mediating these responses to capsaicin has
15 been a more recent development.


The receptor for capsaicin, termed the vanilloid VR1 receptor, was cloned by Caterina and colleagues at UCSF in 1997 (*Nature*, 398:816, 1997). VR1 receptors are cation channels that are found on sensory nerves that innervate the skin, viscera, peripheral tissues and spinal cord. Activation of VR1 elicits action
20 potentials in sensory fibres that ultimately generate the sensation of pain. Importantly VR1 receptor is activated not only by capsaicin but also by acidic pH and by noxious heat stimuli and thus appears to be a polymodal integrator of painful stimuli.

The prototypical VR1 antagonist is capsazepine (Walpole *et al.*,
25 *J. Med. Chem.*, 37:1942, 1994). This has only micromolar affinity for VR1 and is non-specific in its action. A novel series of sub-micromolar antagonists has also been reported recently (Lee *et al*, *Bioorg. Med. Chem.*, 9:1713, 2001), but these reports provide no evidence for *in vivo* efficacy. A much higher affinity antagonist has been derived from the 'ultra-potent' agonist resiniferatoxin.
30 Iodo-resiniferatoxin (Wahl *et al.*, *Mol. Pharmacol.*, 59:9, 2001) is a nanomolar antagonist of VR1 but does not possess properties suitable for an oral pharmaceutical. This last is also true of the micromolar peptoid antagonists described by Garcia-Martinez (*Proc. Natl. Acad. Sci., USA*, 99:2374, 2002). Most recently International (PCT) patent publication No. WO 02/08221 has described a

novel series of VR1 antagonists, which are stated to show efficacy in a number of animal models. We herein describe another novel series of VR1 modulators. These comprise predominantly VR1 antagonists but encompass VR1 partial antagonists and VR1 partial agonists. Such compounds have been shown to be efficacious in animal models of pain.

Structurally related compounds are disclosed in EP-A-0418071, WO-A-9104027, WO-A-9324458, US-A-5596001 and US-A-5362818 all in the name of Pfizer Inc., WO-A-0064888 and WO-A-0064876 in the name of Aventis Pharmaceutical Products Inc. and WO-A-9406280 in the name of The Regents of the University of California. None of the compounds disclosed are for treating pain.

The present invention provides compounds of formula (I):



wherein

A, B, D and E are each C or N with the proviso that one or more are N;
 R¹ and R² are each independently hydrogen, halogen, hydroxy, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₃₋₇cycloalkyl, C₃₋₅cycloalkylC₁₋₄alkyl, NR⁷R⁸, carboxy, esterified carboxy, C₁₋₆alkyl substituted with a group selected from NR⁷R⁸, carboxy and esterified carboxy, or C₁₋₆alkoxy substituted with a group selected from NR⁷R⁸, carboxy and esterified carboxy;
 R³ and R⁴ are each independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl;
 R⁵ and R⁶ are, at each occurrence, independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆acyloxy, carboxy, esterified carboxy, CONR⁷R⁸, SO₂R⁷, SO₂NR⁷R⁸, aryl, heteroaryl, heterocyclyl, or C₁₋₆alkyl substituted with a group selected from hydroxy, C₁₋₆alkoxy, C₁₋₆acyloxy, carboxy, esterified carboxy, NR⁷R⁸, CONR⁷R⁸, SR⁷, SO₂R⁷, SO₂NR⁷R⁸, aryl, heteroaryl and heterocyclyl;

- or R⁵ and R⁶ and the carbon atom to which they are attached together form a carbocyclic ring of 3 to 6 carbon atoms;
- R⁷ and R⁸ are, at each occurrence, independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl or fluoroC₁₋₆alkyl;
- 5 or R⁷ and R⁸ and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C₁₋₄alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, a group S(O) or S(O)₂, or a second nitrogen atom which will be part of a NH or NR^a moiety where R^a is
- 10 C₁₋₄alkyl optionally substituted by hydroxy or C₁₋₄alkoxy;
- X is an oxygen or sulfur atom or the group =NCN;
- Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; and
- n is either zero or an integer from 1 to 3;
- or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.
- 15 R¹ may be absent or one or two R¹ groups may be present, as a preferred embodiment. R¹ is thus preferably chosen independently from halogen, haloC₁-alkyl and C₁₋₆alkoxy, such as fluorine, chlorine, trifluoromethyl and methoxy.
- A preferred class of compound of formula (I) is that wherein R¹ is a hydrogen or halogen atom or a group selected from C₁₋₆alkyl and C₁₋₆alkoxy.
- 20 More particularly, a preferred class of compound of formula (I) is that wherein R¹ is a hydrogen or a halogen atom, particularly a hydrogen or a fluorine atom, and most especially a hydrogen atom.
- Where R¹ is other than hydrogen, preferably there is only one R¹ substituent.
- 25 Generally R² is absent or one or two R² groups are present. Thus R² is preferably independently chosen from C₁₋₆alkoxy, halogen, di(C₁₋₆alkyl)amino, C₁₋₆alkyl, hydroxy, C₁₋₆alkoxycarbonyl, carboxy, amino, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl and aminoC₁₋₆alkyl. More preferably R² is independently chosen from halogen, hydroxy, carboxy, amino, C₁₋₃alkoxy, di(C₁₋₃alkyl)amino, C₁₋₃alkyl, C₁₋₃alkoxycarbonyl, haloC₁₋₃alkyl, hydroxyC₁₋₃alkyl and aminoC₁₋₃alkyl. R² is particularly chosen independently from methoxy, methyl, ethyl, chlorine, dimethylamino, hydroxy, trifluoromethyl, methoxycarbonyl, carboxy, amino, hydroxymethyl and aminoethyl.

Another preferred class of compound of formula (I) is that wherein R² is a hydrogen or halogen atom or a group selected from C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy, NR⁷R⁸, C₁₋₆alkyl substituted with NR⁷R⁸, and C₁₋₆alkoxy substituted with NR⁷R⁸, wherein R⁷ and R⁸ each independently preferably represent

5 hydrogen atoms or C₁₋₄alkyl groups.

A further preferred class of compound of formula (I) is that wherein R² is a hydrogen or a halogen atom, or a group selected from C₁₋₄alkyl, C₁₋₄alkoxy and NR⁷R⁸, wherein R⁷ and R⁸ each independently preferably represent hydrogen atoms or C₁₋₄alkyl groups.

10 More particularly, R² preferably represents a hydrogen or chlorine atom or a group selected from methyl, methoxy and dimethylamino. Most preferably, R² is a hydrogen atom.

Where R² is other than hydrogen, preferably there is only one R² substituent.

15 Thus quinoline, isoquinoline and cinnoline moieties included within the scope of the invention include isoquinolin-5-yl, isoquinolin-8-yl, quinolin-5-yl, 2-oxidoisoquinolin-5-yl, 3-methoxyisoquinolin-8-yl, cinnolin-5-yl, 3-methylisoquinolin-5-yl, 1-chloroisoquinolin-5-yl, 1-dimethylaminoisoquinolin-5-yl, 3-methylisoquinolin-8-yl, 3-chloroisoquinolin-5-yl, 3-methylcinnolin-5-yl, 8-fluoroisoquinolin-5-yl, 1-hydroxyisoquinolin-5-yl, 3-trifluoromethylisoquinolin-5-yl, 1-chloro-3-ethylisoquinolin-5-yl, 1-methylisoquinolin-5-yl, 6,8-difluoro-3-methylisoquinolin-5-yl, 7-trifluoromethyl-3-methylisoquinolin-5-yl, 3-methyl-8-fluoroisoquinolin-5-yl, 3-methyl-6-fluoroisoquinolin-5-yl, 7-methoxyisoquinolin-5-yl, 1,3-dimethylisoquinolin-5-yl, 3-methyl-7-chloroisoquinolin-5-yl, 7-chloroisoquinolin-5-yl, 6-fluoroisoquinolin-5-yl, 7-fluoroisoquinolin-5-yl, 4-methylisoquinolin-5-yl, 8-trifluoromethylisoquinolin-5-yl, 6-trifluoromethylisoquinolin-5-yl, 7-trifluoromethylisoquinolin-5-yl, 1-methyl-6-fluoroisoquinolin-5-yl, 1-chloroisoquinolin-5-yl, 1-methoxycarbonylisoquinolin-5-yl, 1-carboxyisoquinolin-5-yl, 1-aminoisoquinolin-5-yl, 1-hydroxymethylisoquinolin-5-yl, 3-methoxycarbonylisoquinolin-5-yl, 3-carboxyisoquinolin-5-yl, 3-dimethylaminoisoquinolin-5-yl, 3-(2-aminoethyl)isoquinolin-5-yl and 8-methoxyisoquinolin-5-yl.

A further preferred class of compound of formula (I) is that wherein R³ is a hydrogen atom or a C₁₋₄alkyl group, particularly a hydrogen atom or a methyl group, and most especially a hydrogen atom.

5 A yet further preferred class of compound of formula (I) is that wherein R⁴ is a hydrogen atom or a C₁₋₄alkyl group, particularly a hydrogen atom or a methyl group, and most especially a hydrogen atom.

10 Another preferred class of compound of formula (I) is that wherein R⁵ and R⁶ each independently represent a hydrogen atom or a group selected from C₁₋₆alkyl, C₁₋₆alkyl substituted by a group selected from hydroxy, C₁₋₆acyloxy, carboxy, esterified carboxy, NR⁷R⁸ and heterocyclyl, or an aryl group

15 More particularly, a preferred class of compound of formula (I) is that wherein R⁵ and R⁶ each independently represent a hydrogen atom or a C₁₋₄alkyl or phenyl group, particularly a hydrogen atom or a methyl group, and most especially a hydrogen atom.

Thus -(CR⁵R⁶)_n- can represent a bond, -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -CH(C₆H₅)CH₂CH₂-, -CHCH₃- and -CH(CH₂COOCH₂CH₃)-.

A further preferred class of compound of formula (I) is that wherein X is an oxygen atom. X may be sulphur or oxygen.

20 A yet further preferred class of compound of formula (I) is that wherein Y is an aryl group selected from unsubstituted phenyl or naphthyl and phenyl or naphthyl substituted by one or two substituents selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, phenyl, cyano, nitro, pyrazolyl, di(C₁₋₆alkyl)amino, phenoxy, -OCH₂O- and C₁₋₆alkylcarbonyl; or a heteroaryl group selected from pyridyl, thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl
25 wherein each heteroaryl group is optionally substituted with one or two substituents selected from C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, unsubstituted heteroaryl or phenyl which may be substituted by C₁₋₆alkyl or halogen; or a carbocyclyl group which is a C₅₋₇cycloalkyl radical that is unsubstituted or substituted by a phenyl ring; or a fused-carbocyclyl group which
30 is a C₅₋₇cycloalkyl radical that is fused to a phenyl ring.

A yet further preferred class of compound of formula (I) is that wherein Y is an aryl group selected from unsubstituted phenyl and phenyl substituted by one or two substituents selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, phenyl and pyrazolyl; or a heteroaryl group selected from pyridyl,

thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl wherein each heteroaryl group is optionally substituted with one or two substituents selected from C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, phenyl; or a carbocyclyl group which is a C₅₋₇cycloalkyl radical that is unsubstituted or substituted by a phenyl ring; or a fused-carbocyclyl group which is a C₅₋₇cycloalkyl radical that is fused to a phenyl ring.


Thus Y can be phenyl, biphen-4-yl, biphen-3-yl,
1,2,3,4-tetrahydronaphthalen-2-yl, 4-chlorophenyl, 3,5-di(trifluoromethyl)phenyl,
3,4-dimethylphenyl, 4-tertbutylphenyl, 3-tertbutylphenyl, 3-
10 trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl,
2,3-dihydro-1H-inden-2-yl, 4-phenylcyclohexyl, 6,7,8,9-tetrahydro-5H-
benzo[a][7]annulen-6-yl, 6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-yl,
3-trifluoromethylpyridin-6-yl, 4-tertbutylpyridin-6-yl, 2-tertbutylpyridin-5-yl,
2-tertbutylpyridin-4-yl, 2-tertbutylpyridin-6-yl, 2-trifluoromethylpyridin-5-yl,
15 2-(pyrazol-1-yl)phenyl, 4-(pyrazol-1-yl)phenyl, 2-phenylthiazol-5-yl, 2-(thiophen-
2-yl)thiazol-3-yl, 3-phenylthiazol-2-yl, 5-phenylisoxazol-3-yl, 3-phenylisoxazol-5-
yl, 3-phenyloxadiazol-5-yl, 2-benzylthiazol-4-yl, 1-(2-methylphenyl)pyrazol-4-yl,
cyclohexyl, naphthalen-2-yl, 4-cyanophenyl, 4-nitrophenyl,
4-dimethylaminophenyl, 4-phenoxyphenyl, 1,3-benzodioxol-5-yl,
20 4-methylcarbonylphenyl, isoquinolin-6-yl, 4-(morpholin-4-ylmethyl)phenyl and
2-(2-morpholin-4-ylethoxy)phenyl.

Another preferred class of compound of formula (I) is that wherein one of A, B, D and E is a nitrogen atom and the other three are carbon atoms, or A and B are nitrogen atoms and D and E are carbon atoms.

25 It will be appreciated that the group R² is attached to any available carbon atom represented by A, B, D and E.

When present, R⁷ is preferably a hydrogen atom or a C₁₋₄alkyl group, and R⁸ is preferably a hydrogen atom or a C₁₋₄alkyl group, or the group NR⁷R⁸ represents a heteroaliphatic ring selected from azetidinyl, pyrrolidinyl,
30 piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl or a piperazinyl group substituted on the nitrogen atom by C₁₋₄alkyl optionally substituted by hydroxy or C₁₋₄alkoxy. More preferably, the group NR⁷R⁸ represents a group selected from -NH₂, -NHCH₃, -N(CH₃)₂, -NHCH₂CH₃, -N(CH)CH₂CH₃ and -N(CH₂CH₃)₂, and most especially, -N(CH₃)₂.


One favoured class of compound of the present invention is that of formula (Ia) and pharmaceutically acceptable salts, N-oxides and prodrugs thereof:



5

With reference to formula (Ia), preferably E is a carbon atom. Also preferred are those compounds of formula (Ia) where E is a carbon atom, one of A, B and D is a nitrogen atom and the others are carbon atoms, or where A and B are nitrogen atoms and D and E are carbon atoms.

10 Another favoured class of compound of the present invention is that of formula (Ib) and pharmaceutically acceptable salts, N-oxides and prodrugs thereof:



15

With reference to formula (Ib), preferably E is a carbon atom. Also preferred are those compounds of formula (Ib) where E is a carbon atom, one of A, B and D is a nitrogen atom and the others are carbon atoms, or where A and B are nitrogen atoms and D and E are carbon atoms. With reference to compounds 20 of formula (Ib), preferably, A is a nitrogen atom and B, D and E are carbon atoms.

When any variable occurs more than one time in formula (I), formula (Ia) or formula (Ib) or in any substituent, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, 5 n-butoxy, s-butoxy and t-butoxy.

As used herein, the term "hydroxyC₁₋₆alkyl" means a C₁₋₆alkyl group in which one or more (in particular 1 to 3, and especially 1) hydrogen atoms have been replaced by hydroxy groups. Particularly preferred are hydroxyC₁₋₆alkyl groups, for example, CH₂OH, CH₂CH₂OH, CH(CH₃)OH or C(CH₃)₂OH, and most 10 especially CH₂OH.

As used herein, the terms "haloC₁₋₆alkyl" and "haloC₁₋₆alkoxy" means a C₁₋₆alkyl or C₁₋₆alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. Preferred are fluoroC₁₋₆alkyl and fluoroC₁₋₆alkoxy groups, in particular, 15 fluoroC₁₋₃alkyl and fluoroC₁₋₃alkoxy groups, for example, CF₃, CH₂CH₂F, CH₂CHF₂, CH₂CF₃, OCF₃, OCH₂CH₂F, OCH₂CHF₂ or OCH₂CF₃, and most especially CF₃, OCF₃ and OCH₂CF₃.

The cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Suitable C₈₋₇cycloalkylC₁₋₄alkyl groups include, for example, cyclopropylmethyl and cyclohexylmethyl. 20

Similarly cycloalkoxy groups referred to herein may represent, for example, cyclopropoxy or cyclobutoxy.

As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable 25 alkenyl groups include vinyl and allyl. A suitable alkynyl group is acetylene or propargyl.

When used herein, the term "halogen" means fluorine, chlorine, bromine and iodine. The most apt halogens are fluorine and chlorine of which fluorine is preferred, unless otherwise stated.

30 When used herein, the term "carboxy" as a group or part of a group denotes CO₂H.

When used herein, the term "esterified carboxy" denotes a C₁₋₆alkoxy or a haloC₁₋₆alkoxy radical attached via the oxygen atom thereof to a carbonyl (C=O) radical thus forming a C₁₋₆alkoxycarbonyl or haloC₁₋₆alkoxycarbonyl radical.

Suitable examples of such esterified carboxy groups include, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl and *tert*-butoxycarbonyl.

When used herein, the term "acyloxy" denotes a C₁₋₆alkyl or a haloC₁₋₆alkyl radical attached to a carbonyl (C=O) radical thus forming a C₁₋₆alkoyl or haloC₁₋₆alkanoyl radical which is attached via the carbonyl (C=O) radical to an oxygen atom. Suitable examples of such esterified carboxy groups include, for example, acetoxy, propionyloxy, isopropionyloxy and trifluoroacetoxy.

As used herein, the term "aryl" as a group or part of a group means an aromatic radical such as phenyl, biphenyl or naphthyl, wherein said phenyl, biphenyl or naphthyl group may be optionally substituted by one, two or three groups independently selected from halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, NR^bR^s, benzyl, NO₂, cyano, SR^b, SOR^b, SO₂R^b, COR^b, CO₂R^b, CONR^bR^c, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₄alkoxyC₁₋₄alkyl, -O(CH₂)_mO- or a heteroaromatic group selected from furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyridyl substituted by a group selected from halogen, haloC₁₋₆alkyl and haloC₁₋₆alkoxy (where R^b and R^c each independently represent hydrogen, C₁₋₄alkyl, C₃₋₅cycloalkyl or fluoroC₁₋₄alkyl or R^b and R^c, together with the nitrogen atom to which they are attached form a piperidine, piperazine or morpholine ring and m is 1 or 2).

As used herein, the term "aryl" as a group or part of a group means an aromatic radical such as phenyl, biphenyl or naphthyl, wherein said phenyl, biphenyl or naphthyl group may be optionally substituted by one, two or three groups independently selected from halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, NR^bR^s, benzyl, NO₂, cyano, SR^b, SOR^b, SO₂R^b, COR^b, CO₂R^b, CONR^bR^c, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₄alkoxyC₁₋₄alkyl, -O(CH₂)_mO- or a heteroaromatic group selected from furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyridyl substituted by a group selected from halogen, haloC₁₋₆alkyl and haloC₁₋₆alkoxy (where R^b and R^c each independently represent hydrogen, C₁₋₄alkyl, C₃₋₅cycloalkyl or fluoroC₁₋₄alkyl and m is 1 or 2).

Preferably said phenyl, biphenyl or naphthyl group is optionally substituted by one or two substituents, especially none or one. Particularly

preferred substituents include fluorine, chlorine, C₁₋₄alkyl (especially methyl or t-butyl), C₁₋₄alkoxy (especially methoxy), trifluoromethyl or trifluoromethoxy.

As used herein, the term "heteroaryl" as a group or part of a group means a 5 or 6-membered monocyclic heteroaromatic radical containing from 1 to 4 nitrogen atoms or an oxygen atom or a sulfur atom, or a combination thereof, or an 8- to 10-membered bicyclic heteroaromatic radical containing from 1 to 4 nitrogen atoms or an oxygen atom or a sulfur atom or a combination thereof. Suitable examples include pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl and cinnolinyl, wherein said heteroaromatic radicals may be optionally substituted by one, two or three groups independently selected from halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, NR^bR⁸, phenyl, phenyl substituted by a group selected from halogen, haloC₁₋₆alkyl and haloC₁₋₆alkoxy, benzyl, NO₂, cyano, SR^b, SOR^b, SO₂R^b, COR^b, CO₂R^b, CONR^bR^c, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₄alkoxyC₁₋₄alkyl, -O(CH₂)_mO- or an additional heteroaromatic group selected from furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyridyl substituted by a group selected from halogen, haloC₁₋₆alkyl and haloC₁₋₆alkoxy (where R^b, R^c and m are as previously defined).

Preferably said heteroaromatic radical is optionally substituted by one or two substituents, especially none or one. Particularly preferred substituents include C₁₋₄alkyl (especially methyl or *tert*-butyl), C₁₋₄alkoxy (especially methoxy), trifluoromethyl, trifluoromethoxy, phenyl, phenyl substituted by halogen (especially fluorine) and C₁₋₄alkyl (especially methyl), benzyl, or thienyl.

As used herein, the term "carbocyclyl" as a group or part of a group means a 3 to 7-membered cycloalkyl radical such as cyclobutyl, cyclopentyl or cyclohexyl, wherein said cycloalkyl radical may be optionally substituted by one, two or three groups independently selected from halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, NR^bR⁸, phenyl, phenyl substituted by a group selected from halogen, haloC₁₋₆alkyl and haloC₁₋₆alkoxy, benzyl, NO₂, cyano, NR^bR^c, SR^b, SOR^b, SO₂R^b, COR^b, CO₂R^b, CONR^bR^c, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₄alkoxyC₁₋₄alkyl, -O(CH₂)_mO- or a heteroaromatic group selected from furanyl,

pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyridyl substituted by a group selected from halogen, haloC₁₋₆alkyl and haloC₁₋₆alkoxy (where R^b, R^c and m are as previously defined).

- 5 Preferably said carbocyclyl group is optionally substituted by one or two substituents, especially none or one. A particularly preferred substituent is phenyl.

As used herein, the term "fused-carbocyclyl" as a group or part of a group means a 3 to 7-membered cycloalkyl radical such as cyclobutyl, cyclopentyl, 10 cyclohexyl, or cycloheptyl, wherein said cycloalkyl radical is fused to an aryl or heteroaryl group as herein defined. Preferably, said fused-carbocyclyl group is attached to the remainder of the molecule via a carbon atom of the cycloalkyl radical. Preferably, said cycloalkyl radical is fused to a phenyl or pyridyl ring where said phenyl ring is optionally substituted by a group selected from halogen 15 (especially fluorine) and fluoroC₁₋₄alkyl (especially trifluoromethyl), furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, and said pyridyl ring is optionally substituted by a group selected from halogen (especially fluorine) and fluoroC₁₋₄alkyl (especially trifluoromethyl). Preferably said cycloalkyl radical is fused to a phenyl ring.

- 20 Particular compounds of the invention include:

N-benzyl-N'-isoquinolin-5-ylurea
N-(1,1'-biphenyl-4-ylmethyl)-N'-isoquinolin-5-ylurea
N-(1,1'-biphenyl-3-ylmethyl)-N'-isoquinolin-5-ylurea
N-isoquinolin-5-yl-N'-(3-phenylpropyl)urea;
25 N-isoquinolin-5-yl-N'-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)urea;
N-[2-(4-chlorophenyl)ethyl]-N'-isoquinolin-5-ylurea;
N-[3,5-bis(trifluoromethyl)benzyl]-N'-isoquinolin-5-ylurea;
N-[3-(3,4-dimethylphenyl)propyl]-N'-isoquinolin-5-ylurea;
N-(4-tert-butylbenzyl)-N'-isoquinolin-8-ylurea;
30 N-(4-tert-butylbenzyl)-N'-isoquinolin-5-ylurea;
N-(4-tert-butylbenzyl)-N'-quinolin-5-ylurea;
N-(3-tert-butylbenzyl)-N'-isoquinolin-5-ylurea;
N-[2-(4-tert-butylphenyl)ethyl]-N'-isoquinolin-5-ylurea;
N-isoquinolin-5-yl-N'-[4-(trifluoromethyl)benzyl]urea;

- N*-isoquinolin-5-yl-*N*^r-[3-(trifluoromethyl)benzyl]urea;
N-isoquinolin-5-yl-*N*^r-{2-[4-(trifluoromethyl)phenyl]ethyl}urea;
N-(2-oxidoisoquinolin-5-yl)-*N*^r-[4-(trifluoromethyl)benzyl]urea;
N-isoquinolin-5-yl-*N*^r-{2-[3-(trifluoromethyl)phenyl]ethyl}urea;
- 5 *N*-isoquinolin-5-yl-*N*^r-{3-[4-(trifluoromethyl)phenyl]propyl}urea;
N-isoquinolin-8-yl-*N*^r-[4-(trifluoromethyl)benzyl]urea;
N-[3-fluoro-4-(trifluoromethyl)benzyl]-*N*^r-isoquinolin-5-ylurea;
N-[2-fluoro-4-(trifluoromethyl)benzyl]-*N*^r-isoquinolin-5-ylurea;
10 *N*-isoquinolin-5-yl-*N*^r-{3-[3-(trifluoromethyl)phenyl]propyl}urea;
N-isoquinolin-5-yl-*N*^r-[4-(trifluoromethoxy)benzyl]urea;
N-{[6-(4-fluorophenyl)pyridin-3-yl]methyl}-*N*^r-isoquinolin-5-ylurea;
N-isoquinolin-8-yl-*N*^r-{3-[4-(trifluoromethyl)phenyl]propyl}urea;
15 *N*-quinolin-5-yl-*N*^r-{3-[4-(trifluoromethyl)phenyl]propyl}urea;
N-isoquinolin-8-yl-*N*^r-{3-[3-(trifluoromethyl)phenyl]propyl}urea;
N-quinolin-5-yl-*N*^r-{3-[3-(trifluoromethyl)phenyl]propyl}urea;
20 *N*-isoquinolin-8-yl-*N*^r-[4-(trifluoromethoxy)benzyl]urea;
N-quinolin-5-yl-*N*^r-[4-(trifluoromethoxy)benzyl]urea;
N-(2,3-dihydro-1*H*-inden-2-ylmethyl)-*N*^r-isoquinolin-5-ylurea;
N-isoquinolin-5-yl-*N*^r-(4-phenylcyclohexyl)urea;
25 *N*-isoquinolin-5-yl-*N*^r-(6,7,8,9-tetrahydro-5*H*-benzo[a][7]annulen-6-ylmethyl)urea;
N-isoquinolin-5-yl-*N*^r-(6,7,8,9-tetrahydro-5*H*-benzo[a][7]annulen-7-ylmethyl)urea;
N-isoquinolin-5-yl-*N*^r-{[5-(trifluoromethyl)pyridin-2-yl]methyl}urea;
30 *N*-[(4-*tert*-butylpyridin-2-yl)methyl]-*N*^r-isoquinolin-5-ylurea;
N-[(6-*tert*-butylpyridin-3-yl)methyl]-*N*^r-isoquinolin-5-ylurea;
N-[(2-*tert*-butylpyridin-4-yl)methyl]-*N*^r-isoquinolin-5-ylurea;
N-[(6-*tert*-butylpyridin-2-yl)methyl]-*N*^r-isoquinolin-5-ylurea;
35 *N*-isoquinolin-5-yl-*N*^r-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea;
N-isoquinolin-5-yl-*N*^r-{3-[6-(trifluoromethyl)pyridin-3-yl]propyl}urea;
N-isoquinolin-5-yl-*N*^r-[3-(1*H*-pyrazol-1-yl)benzyl]urea;
40 *N*-isoquinolin-5-yl-*N*^r-[4-(1*H*-pyrazol-1-yl)benzyl]urea;
N-isoquinolin-5-yl-*N*^r-[(2-phenyl-1,3-thiazol-5-yl)methyl]urea;
N-isoquinolin-5-yl-*N*^r-[(2-thien-2-yl-1,3-thiazol-4-yl)methyl]urea;
45 *N*-isoquinolin-5-yl-*N*^r-[(4-phenyl-1,3-thiazol-2-yl)methyl]urea;
N-isoquinolin-5-yl-*N*^r-[(2-phenyl-1,3-thiazol-4-yl)methyl]urea;

- N*-isoquinolin-5-yl-*N'*-[2-(4-phenyl-1,3-thiazol-2-yl)ethyl]urea;
N-isoquinolin-5-yl-*N'*-[(5-phenylisoxazol-3-yl)methyl]urea;
N-isoquinolin-5-yl-*N'*-[(3-phenylisoxazol-5-yl)methyl]urea;
N-(8-fluoroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
- 5 *N*-isoquinolin-5-yl-*N*-methyl-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-isoquinolin-5-yl-*N*-methyl-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-isoquinolin-5-yl-*N'*-{1-[4-(trifluoromethyl)phenyl]ethyl}urea;
N-(1,3-diphenylpropyl)-*N'*-isoquinolin-5-ylurea;
N-isoquinolin-5-yl-*N'*-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]urea;
- 10 *N*-[(2-benzyl-1,3-thiazol-4-yl)methyl]-*N'*-isoquinolin-5-ylurea;
N-isoquinolin-5-yl-*N'*-{[1-(2-methylphenyl)-1*H*-pyrazol-4-yl]methyl}urea;
N-(3-methoxyisoquinolin-8-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-cinnolin-5-yl-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-(4-*tert*-butylbenzyl)-*N'*-cinnolin-5-ylurea;
- 15 *N*-(3-cyclohexylpropyl)-*N'*-isoquinolin-5-ylurea;
N-isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[a][7]annulen-7-yl)urea;
N-isoquinolin-5-yl-*N'*-[4-(trifluoromethyl)benzyl]thiourea;
N-isoquinolin-6-yl-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-isoquinolin-6-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea;
- 20 *N*-(3-methylisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-(1-chloroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-[1-(dimethylamino)isoquinolin-5-yl]-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-(3-methylisoquinolin-5-yl)-*N'*-[4-(trifluoromethoxy)benzyl]urea;
N-(3-methylisoquinolin-8-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
- 25 *N*-(3-chloroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-(3-methylcinnolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-cinnolin-5-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea;
N-(1-hydroxyisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-[4-(trifluoromethyl)benzyl]-*N'*-[3-(trifluoromethyl)isoquinolin-5-yl]urea;
- 30 *N*-(1-chloro-3-ethylisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea;
N-phenyl-*N'*-[quinolin-6-yl]urea;
N-(2-naphthyl)-*N'*-[quinolin-6-yl]urea;
N-(4-nitrophenyl)-*N'*-[quinolin-6-yl]urea;
N-[3,5-bis(trifluoromethyl)phenyl]-*N'*-[quinolin-6-yl]urea;

- N*-(4-phenoxyphenyl)-*N'*-[quinolin-6-yl]urea;
N-(4-acetylphenyl)-*N'*-[quinolin-6-yl]urea;
N-benzyl-*N'*-[quinolin-6-yl]urea;
N-[quinolin-6-yl]-*N'*-[4-(trifluoromethoxy)phenyl]urea;
- 5 *N*-(4-cyanophenyl)-*N'*-[quinolin-6-yl]urea;
N-(1,1'-biphenyl-4-yl)-*N'*-[quinolin-6-yl]urea;
N-[4-(dimethylamino)phenyl]-*N'*-[quinolin-6-yl]urea;
N-(1,3-benzodioxol-5-yl)-*N'*-[quinolin-6-yl]urea;
N-cyclohexyl-*N'*-[quinolin-6-yl]urea;
- 10 *N*-[(+/-)-1-phenylethyl]-*N'*-[quinolin-6-yl]urea;
N-(1-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(1-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethoxy)benzyl]urea;
N-(6,8-difluoro-3-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
15 *N*-[3-methyl-7-(trifluoromethyl)isoquinolin-5-yl]-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(8-fluoro-3-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(6-fluoro-3-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(6-fluoro-3-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethoxy)benzyl]urea;
20 *N*-(3-methylcinnolin-5-yl)-*N*-[4-(trifluoromethoxy)benzyl]urea;
N-(7-methoxyisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(1,3-dimethylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(7-chloro-3-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
25 *N*-(7-chloroisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(8-fluoro-3-methoxyisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(6-fluoroisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(6-fluoroisoquinolin-5-yl)-*N*-[4-(trifluoromethoxy)benzyl]urea;
30 *N*-(7-fluoroisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(4-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-[8-(trifluoromethyl)isoquinolin-5-yl]-*N*-[4-(trifluoromethyl)benzyl]urea;
N-[6-(trifluoromethyl)isoquinolin-5-yl]-*N*-[4-(trifluoromethyl)benzyl]urea;
N-[7-(trifluoromethyl)isoquinolin-5-yl]-*N*-[4-(trifluoromethyl)benzyl]urea;
N-[7-(trifluoromethyl)isoquinolin-5-yl]-*N*-[4-(trifluoromethoxy)benzyl]urea;
35 *N*-(6-fluoro-1-methylisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;
N-(1-cyanoisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea;

- N-[1-(methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea;
N-(1-carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea;
N-(1-aminoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea;
N-[1-(hydroxymethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea;
- 5 N-[3-(methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea;
N-(3-carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea;
N-[3-(dimethylamino)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea;
N-[3-(2-aminoethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea;
N-(8-methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea;
- 10 N-isoquinolin-7-yl-N'-[4-(trifluoromethyl)benzyl]urea;
N-N'-diisoquinolin-5-ylurea;
N-isoquinolin-5-yl-N'-[4-(trifluoromethyl)phenyl]urea;
N-isoquinolin-5-yl-N'-{[2-(trifluoromethyl)pyrimidin-5-yl]methyl}urea;
ethyl 3-{[(isoquinolin-5-ylamino)carbonyl]amino}-2-[4-(trifluoromethyl)benzyl]
15 propanoate;
3-{[(isoquinolin-5-ylamino)carbonyl]amino}-2-[4-(trifluoromethyl)benzyl]propanoic
acid;
N-isoquinolin-5-yl-N'-[4-(morpholin-4-ylmethyl)benzyl]urea; and
N-isoquinolin-5-yl-N'-[2-(2-morpholin-4-ylethoxy)-4-(trifluoromethyl)benzyl]urea;
- 20 or a pharmaceutically acceptable salt or N-oxide thereof.

In a further aspect of the present invention, the compounds of formula (I) may be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.

For use in medicine, the salts of the compounds of formula (I) will be
25 non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound
30 according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic

group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The salts may be formed by conventional means, such as by reacting the free base form of the compound of formula (I) with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

The present invention also includes within its scope N-oxides of the compounds of formula (I) above. In general, such N-oxides may be formed on any available nitrogen atom, and preferably on any one of A, B, D or E where they represent a nitrogen atom. The N-oxides may be formed by conventional means, such as reacting the compound of formula (I) with oxone in the presence of wet alumina.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible *in vivo* into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation *in vivo* may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.

The compounds according to the invention may have one or more asymmetric centres, and may accordingly exist both as enantiomers and as

diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, the compounds of formula (I) may also exist in tautomeric forms and the invention includes within its scope both mixtures and separate individual
5 tautomers.

It will be appreciated that the preferred definitions of the various substituents recited herein may be taken alone or in combination and, unless otherwise stated, apply to the generic formula for compounds of the present invention as well as to the preferred classes of compound represented by formula
10 (Ia) and formula (Ib).

The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier or excipient.

Preferably the compositions according to the invention are in unit dosage
15 forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices, suppositories, creams or gels; for oral, parenteral, intrathecal, intranasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation. Oral compositions such as tablets, pills, capsules or
20 wafers are particularly preferred. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid pre-formulation
25 composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms
30 such as tablets, pills and capsules. This solid pre-formulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit dosage forms contain from 1 to 500 mg, for example 1, 5, 10, 25, 50, 100, 300 or 500 mg, of the active ingredient. The tablets or pills of the novel composition can

be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric 5 layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

10 The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or 15 suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of painful conditions such as those listed below, a suitable dosage level is about 1.0 mg to 15 g per day, preferably about 5.0 mg to 20 5 g per day, and especially about 20 mg to 2 g day. The compounds may be administered on a regimen of 1 to 4 times per day.

It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the 25 nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.

The invention further provides a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body. Preferably, said treatment is for a condition which is 30 susceptible to treatment by modulation (preferably antagonism) of VR1 receptors.

The compounds of the present invention will be of use in the prevention or treatment of diseases and conditions in which pain and/or inflammation predominates, including chronic and acute pain conditions. Such conditions include rheumatoid arthritis; osteoarthritis; post-surgical pain; musculo-skeletal

pain, particularly after trauma; spinal pain; myofascial pain syndromes; headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain; episiotomy pain; burns, and especially primary hyperalgesia associated
5 therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, pain associated with cystitis and labour pain; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions,
10 amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; itching conditions including pruritis, itch due to hemodialysis, and contact dermatitis; pain (as well as broncho-constriction and inflammation) due to exposure (e.g. via ingestion, inhalation, or eye contact) of mucous membranes to capsaicin and related irritants such as tear gas, hot
15 peppers or pepper spray; neuropathic pain conditions such as diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia; “non-painful” neuropathies; complex regional pain syndromes; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica and
20 ankylosing spondylitis; gout; scar pain; irritable bowel syndrome; inflammatory bowel disease; urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity; respiratory diseases including chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis and asthma; autoimmune diseases; and immunodeficiency disorders.

25 Thus, according to a further aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity.

The present invention also provides a method for the treatment or
30 prevention of physiological disorders that may be ameliorated by modulating VR1 activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).

According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

5 The present invention also provides a method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).

10 According to a further aspect of the present invention, it may be desirable to treat any of the aforementioned conditions with a combination of a compound according to the present invention and one or more other pharmacologically active agents suitable for the treatment of the specific condition. The compound of formula (I) and the other pharmacologically active agent(s) may be
15 administered to a patient simultaneously, sequentially or in combination. Thus, for example, for the treatment or prevention of pain and/or inflammation, a compound of the present invention may be used in conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, as well as opioid
20 analgesics, especially morphine, NR2B antagonists, bradykinin antagonists, anti-migraine agents, anticonvulsants such as oxcarbazepine and carbamazepine, antidepressants (such as TCAs, SSRIs, SNRIs, substance P antagonists, etc.), spinal blocks, gabapentin, pregabalin and asthma treatments (such as β₂-adrenergic receptor agonists or leukotriene D₄antagonists (e.g. montelukast)).

25 Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, nabumetone, ketoprofen, naproxen, piroxicam and sulindac, etodolac, meloxicam, rofecoxib, celecoxib, etoricoxib, parecoxib, valdecoxib and tilicoxib. Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine,
30 hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Suitable anti-migraine agents of use in conjunction with a compound of


the present invention include CGRP-antagonists, ergotamines or 5-HT₁ agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.

Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.

In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.


According to a general process (A), compounds of formula (I) may be prepared by the reaction of a compound of formula (II) with a compound of formula (III):

15



The reaction is conveniently effected at a temperature between 20°C and the reflux temperature of the solvent. Suitable solvents include a halogenated hydrocarbon, for example, dichloromethane.


Similarly, according to a general process (B), compounds of formula (I) may also be prepared by the reaction of a compound of formula (IV) with a compound of formula (V):



The reaction is essentially effected in the same manner as general process

(A).

According to an alternative general process (C), compounds of formula (I), in which X is an oxygen atom, may be prepared by the reaction of a compound of formula (II) with a compound of formula (VI):




10

The carboxylic acid is first reacted with diphenylphosphoryl azide and triethylamine which forms the corresponding isocyanate by a Curtius rearrangement. The isocyanate may then be reacted *in situ* with the amine of formula (II) by heating at reflux to give the desired compound of formula (I). The reactions are conveniently effected in a suitable solvent such as an aromatic hydrocarbon, for example, toluene.

Similarly, according to a general process (D), compounds of formula (I), in which X is an oxygen atom, may also be prepared by the reaction of a compound of formula (V) with a compound of formula (VII):

20



The reaction is essentially effected in the same manner as general process (C).

5 Further details of suitable procedures will be found in the accompanying Examples. For instance, compounds of formula I can be converted into other compounds of formula I utilising synthetic methodology well known in the art. For example, when R² is a chlorine atom it can be converted to a cyano group using zinc chloride by heating, generally to about 80°C, in the presence of a catalyst such as triphenylphosphine palladium under an inert atmosphere for about three days. When R² is a carboxylic ester it can be hydrolysed in the presence of a basic catalyst to the carboxylic acid by known methods. This compound can be converted to an amine group utilising diphenylphosphoryl azide, generally in the presence of a base such as triethylamine, a solvent such as dioxane, under an inert atmosphere and with heating to about 100°C for about 90 minutes, followed by the addition of water, generally with further heating, for about an hour. The carboxylic ester can be selectively reduced to a hydroxymethyl group with lithium borohydride, generally in a solvent, such as a mixture of tetrahydrofuran and toluene, at 60°C for about 1h.

20 Compounds of formulae (III) and (IV) in which X is an oxygen atom may be prepared in situ, as described in general process (C), or they may be prepared from the corresponding carboxylic acid of formulae (VI) and (VII), respectively, by first being converted into the corresponding acyl halide by reaction with, for example, oxalyl chloride. The acyl halide is then converted into the corresponding acyl azide by reaction with, for example, with sodium azide. The desired isocyanate is then obtained by a conventional Curtius rearrangement by heating the acyl azide at reflux. The reactions are conveniently effected in a


suitable solvent such as a halogenated hydrocarbon, for example, dichloromethane.

Compounds of formula (III) and (IV) in which X is a sulfur atom may be prepared from the corresponding amine of formula (IV) and (II), respectively (wherein R³ and R⁴ are hydrogen), by reaction with 1,1'-thiocarbonyl-2(1H)-pyridone. The reaction is conveniently effected at room temperature in a suitable solvent such as a halogenated hydrocarbon, for example, dichloromethane.

Compounds of formulae (II) to (VII) are either known compounds or may be prepared by conventional methodology well known to one of ordinary skill in the art using, for instance, procedures described in the accompanying Examples, or by alternative procedures which will be readily apparent.

For example, compounds of formula II in which B is a nitrogen atom and A, D and E are carbon atoms, one group R² is present at the 3-position and R³ is hydrogen, can be made by reacting a compound in which the amino group is absent with a mixture of concentrated sulfuric acid and fuming nitric acid at about 0°C for about 30 minutes followed by reduction of the resultant nitro group for example using hydrogen and Lindlar catalyst, in a solvent such as methanol.

This compound can be made by reacting a compound of formula VIII:




20

(VIII)

in which R¹ is as defined above with ammonia, generally at about 80°C for about 5 hours, at a pressure of about 35 psi in a Parr apparatus.

The compound of formula VIII can be made by successively reacting a compound of formula IX:



(IX)

in which R¹ is as defined above with a carbonylating agent such as dichloromethyl methylether in a solvent such as dichloromethane in the presence 5 of a catalyst such as titanium tetrachloride at about room temperature for about an hour. The methoxy group is converted to a hydroxy group using a reagent such as borontribromide in a solvent such as dichloromethane at about room temperature for several hours. This compound is optionally activated, for example by forming the trifluoromethylsulfonate using trifluoromethanesulfonic 10 anhydride generally in the presence of a base such as triethylamine and a solvent such as dichloromethane for about one hour at room temperature. This compound is reacted with a solution of a compound of formula X:




(X)

15 in which R² is as defined above, which solvent is generally DMF, in the presence of a base such as triethylamine and preferably catalysts such as dichlorodi(triphenylphosphine)palladium at about room temperature for two to four hours. An alternative activation can also occur by making the bromide in 20 place of the trifluoromethane sulfonate.

The carbonyl moiety in the compounds of formula VIII can also be produced by selectively reducing a carboxylic acid moiety using a reagent such as borane tetrahydrofuran complex in tetrahydrofuran, at about room temperature for about 4 hours, to the alcohol followed by selective oxidation to the aldehyde 25 using, for example, oxalyl chloride in DMSO in a solvent such as dichloromethane at about room temperature for about an hour.


Compounds of formula II in which one group R² is present at the 3-position, B is nitrogen and A, D and E are carbon can also be made by reacting a compound of formula (XI):



(XI)

in which R^1 is as defined above, with the acetal of a compound of formula
 5 $\text{H}_2\text{NCHR}^2\text{CHO}$, in which R^2 is as defined above, generally at reflux for about 2 hours under Dean/Stark conditions followed by the addition of an acid such as concentrated sulfuric acid at a temperature of about 140°C for about 30 minutes.

Compounds of formula II in which an alkyl group is present at the 1-position can be made by the following sequence. A compound of formula (XII):
 10



in which R^1 and R^2 are as defined above, is reacted with an alkylating agent, such as the appropriate Grignard reagent, generally in a solvent such as
 15 tetrahydrofuran for several hours at about room temperature followed by elimination of water under acidic conditions, to produce the corresponding indene. This is converted to the corresponding epoxide, for example using ozone at a temperature of about -78°C for about 9½ hours. This is followed by reacting with ammonium hydroxide at about room temperature for about 2 days to
 20 produce the isoquinoline which is then nitrated and reduced to produce the amine.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups,
 25 such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W.

McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

5 The following non-limiting Examples serve to illustrate the preparation of compounds of the present invention:

The structures of the products of the following Descriptions and Examples were in most cases confirmed by ^1H NMR.

10

Description 1

2-Cyano-5-(trifluoromethyl)pyridine

To an ice-cooled solution of 5-(trifluoromethyl)pyridin-2-ol (10.24 g, 62.8 mmol) in anhydrous dichloromethane (200 ml) was added triethylamine (9.63 ml, 15 69 mmol), followed by dropwise addition of trifluoromethanesulfonic anhydride (12.68 ml, 75.4 mmol). The resulting mixture was stirred at room temperature for 2 hours. The mixture was washed with water (500 ml) and the aqueous layer extracted with dichloromethane (2 x 100 ml). The combined organic layers were washed with water (2 x 300 ml), brine (150 ml), then dried over Na_2SO_4 , filtered through a 1 inch plug of silica gel and evaporated. The residue was dissolved in anhydrous N,N-dimethylformamide (150 ml) and zinc cyanide (3.98 g, 33.9 mmol) was added followed by tetrakis(triphenylphosphine)palladium(0) ($\text{Pd}(\text{PPh}_3)_4$) (3.56 g, 3.09 mmol). The mixture was degassed and heated at 80 °C overnight. The cooled reaction mixture was diluted with water (600 ml) and extracted with ethyl acetate (3 x 150 ml). The combined organic layers were washed with water (2 x 250 ml), brine (150 ml), dried (Na_2SO_4) and evaporated. The residue was purified by column chromatography on silica eluting with a gradient rising from neat iso-hexanes to 10% Et_2O in iso-hexanes to give the title compound (8 g, 75%) as a white solid.

30

Description 2

2-Aminomethyl-5-(trifluoromethyl)pyridine

To a nitrogen flushed solution of 2-cyano-5-(trifluoromethyl)pyridine (Description 1; 8.0 g, 46.5mmol) in a mixture of ethanol (100 ml) and ammonium hydroxide

(25 ml) was added a spatula end of Raney Nickel and the resulting mixture hydrogenated at 50 psi overnight. The catalyst was removed by filtration and the filtrate was evaporated to dryness. The residue was purified by column chromatography on silica eluting with a gradient rising from 2% MeOH in dichloromethane + 0.5% NH₄OH to 5% MeOH in dichloromethane + 0.5% NH₄OH to give the title compound (2.5 g, 30%) as a yellow oil.

Description 3

4-tert-Butylpyridine-N-Oxide

To a solution of 4-*tert*-butylpyridine (44.3 ml, 300 mmol) in glacial acetic acid (200 ml) was added hydrogen peroxide (37.1 ml of a 27.5 % aqueous solution, 300 mmol), and the resulting mixture heated at reflux overnight. The cooled mixture was evaporated to dryness. The residue was dissolved in dichloromethane (200 ml), and washed with brine (50 ml), then dried (Na₂SO₄) and evaporated to give the title compound (40 g, 88%) as a white solid.

Description 4

2-Cyano-4-tert-butylpyridine

To trimethylsilylcyanide (25.0 ml, 187.5 mmol) was added a solution of 4-*tert*-butylpyridine-N-oxide (Description 3; 22.68 g, 150 mmol) in anhydrous dichloromethane (200 ml). To this mixture was added dropwise a solution of dimethyl carbamoyl chloride (17.26 ml, 187.5 mmol) in anhydrous dichloromethane (50 ml). The reaction mixture was stirred at room temperature for 24 hours. A solution of 10% aqueous K₂CO₃ (200 ml) was added dropwise and the resulting mixture stirred for 10 minutes. The organic layer was separated and the aqueous layer extracted with 2 further portions of dichloromethane (100 ml). The combined organic layers were dried (Na₂SO₄) and evaporated to give the title compound (24 g, 100%).

30

Description 5

2-Aminomethyl-4-tert-butylpyridine

A solution of 2-cyano-4-*tert*-butylpyridine (Description 4; 24.0 g, 150 mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was taken up in dichloromethane (300 ml) and washed with

brine, dried over K_2CO_3 , filtered and evaporated. The residue was purified by column chromatography on silica eluting with 5% MeOH in dichloromethane + 0.5% NH_4OH to give the title compound (12 g, 48%) as a pale yellow oil.

5

Description 6**2-[4-(Trifluoromethyl)phenyl]ethylamine**

A solution of [4-(trifluoromethyl)phenyl]acetonitrile (9.98 g, 53.9mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was purified by column chromatography on silica eluting with 4% MeOH in dichloromethane + 0.5% NH_4OH to give the title compound (6.5 g, 63%) as an orange oil.

10

Description 7**3-*tert*-Butylphenyl trifluoromethane sulfonate**

To an ice-cooled solution of 3-*tert*-butylphenol (10 g, 66.6 mmol) and triethylamine (13.92 ml, 99.9 mmol) in anhydrous dichloromethane (100 ml) under an atmosphere of nitrogen was added slowly trifluoromethanesulfonic anhydride (12.30 ml, 73.26 mmol), and the resulting mixture stirred at room temperature for 2 hours. The mixture was then washed with 1N HCl (100 ml), brine (100 ml), dried (Na_2SO_4) and evaporated. The residue was purified by column chromatography on silica eluting with iso-hexanes to give the title compound (16.38 g, 87%) as a clear oil.

15

20

Description 8**3-*tert*-Butylbenzonitrile**

To a solution of 3-*tert*-butylphenyl trifluoromethane sulfonate (Description 7; 16.37 g, 58 mmol) in anhydrous N,N-dimethylformamide (200 ml) was added zinc cyanide (8.17 g, 69.6 mmol), and $Pd(PPh_3)_4$ (3.35 g, 2.9 mmol) and the mixture was then degassed (N_2) and heated at 80 °C overnight. The cooled reaction mixture was poured into water (750 ml), and extracted with ethyl acetate (3 x 200 ml). The combined organic layers were washed with water (2 x 300 ml), brine (200 ml), dried (Na_2SO_4), filtered through a 1 cm plug of silica and evaporated to give the title compound (7 g, 76%).

30

Description 9**3-tert-Butylbenzylamine**

A solution of 3-*tert*-butylbenzonitrile (Description 8; 7.0 g, 44 mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was taken up in dichloromethane (100 ml), washed with brine, dried (Na_2SO_4), filtered through a short plug of silica and evaporated to give the title compound (5.2 g, 72%) as a red oil.

Description 10**10 2-tert-Butyl-5-cyanopyridine**

To a mixture of 3-cyanopyridine (10 g, 96 mmol), trimethylacetic acid (9.8 g, 96 mmol) and silver nitrate (1.63 g, 9.6 mmol) in 10% aqueous sulfuric acid (100 ml) at 70°C was added dropwise a solution of ammonium peroxodisulfate (21.9 g, 96 mmol) in water (120 ml). After complete addition the mixture was stirred at 70°C for 2 hours. The mixture was cooled and basified by the addition of 33% aqueous NH_4OH , and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with brine (100 ml), dried (Na_2SO_4) and evaporated to give the title compound (15.6 g, 100%).

20

Description 11**3-Aminomethyl-6-*tert* butylpyridine**

A solution of 2-*tert*-butyl-5-cyanopyridine (Description 10; 15.5 g, 97 mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was purified by column chromatography on silica eluting with 5% MeOH in dichloromethane + 0.5% NH_4OH to give the title compound (10.5 g, 66%), as a pale yellow oil.

Description 12**2-*tert*-Butyl-4-cyanopyridine**

30 A mixture of 4-cyanopyridine (10 g, 96 mmol), trimethylacetic acid (9.8 g, 96 mmol), and silver nitrate (1.63 g, 9.6 mmol) in 10% aqueous sulfuric acid (100 ml) at 70°C was treated with a solution of ammonium peroxodisulfate (21.9 g, 96 mmol) in water (120 ml) according to the method of Description 10.

Purification by column chromatography on silica eluting with 10% Et₂O in iso-hexanes gave the title compound (6.5 g, 42%).

Description 13

5 4-Aminomethyl-2-*tert*-butylpyridine

A solution of 2-*tert*-butyl-4-cyanopyridine (Description 12; 6.50 g, 40.6 mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was taken up in dichloromethane (100 ml), washed with brine, dried (Na₂SO₄), filtered through a short plug of silica and evaporated to give the title compound (6.1 g, 91%) as a brown oil.

Description 14

2-Bromo-6-*tert*-butylpyridine

To potassium *tert*-butoxide (1.0M in *tert* butanol, 100 ml, 100 mmol) was added 15 2,6-dibromopyridine (15.87 g, 67 mmol), and the resulting mixture heated at reflux for 3.5 hours. The mixture was evaporated and the residue quenched by the addition of water (150 ml). The mixture was extracted with ethyl acetate (3 x 80 ml) and the combined organic layers washed with brine (100 ml), dried (Na₂SO₄) and evaporated. The residue was purified by column chromatography 20 on silica eluting with 2% Et₂O in iso-hexanes to give the title compound (9.9 g, 69%) as a clear oil.

Description 15

2-*tert*-Butyl-6-cyanopyridine

25 To a solution of 2-bromo-6-*tert*-butylpyridine (Description 14; 9.9 g, 46 mmol) in anhydrous N,N-dimethylformamide (130 ml) was added zinc cyanide (6.48 g, 55.2 mmol) and Pd(PPh₃)₄ (2.65 g, 2.3 mmol). The mixture was degassed then heated at 80 °C overnight. The cooled reaction mixture was poured into water (500 ml), and extracted with ethyl acetate (3 x 150 ml). The combined organic 30 layers were washed with water (2 x 300 ml), brine (100 ml), dried (Na₂SO₄) and evaporated. The residue was purified by column chromatography on silica eluting with 5% Et₂O in iso-hexanes to give the title compound (6.6 g, 89%).

Description 16**2-Aminomethyl-6-tert-butylpyridine**

A solution of 2-*tert*-butyl-6-cyanopyridine (Description 15, 6.6 g, 41.2 mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was taken up into dichloromethane (300 ml) and washed with brine, dried over K₂CO₃, filtered and evaporated. The residue was purified by column chromatography on silica eluting with 5% MeOH in dichloromethane + 0.5% NH₄OH to give the title compound (4.5 g, 66%) as a pale orange oil.

10

Description 17**(E/Z)-3-[6-(Trifluoromethyl)pyridin-3-yl]prop-2-enenitrile**

To an ice-bath cooled suspension of sodium hydride (1.26 g of a 60% dispersion, 31.46 mmol) in anhydrous THF (75 ml) was added dropwise a solution of diethyl cyanomethylphosphonate (5.09 ml, 31.46 mmol) in THF (50 ml). After the addition was complete the mixture was stirred for 10 minutes then a solution of 6-(trifluoromethyl)pyridine-3-carboxaldehyde (5.00 g, 28.6 mmol) in THF (25 ml) was added and the resulting mixture stirred at room temperature for 1 hour. Water (250 ml) was added and the mixture extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with water (x2), brine, dried (Na₂SO₄) and evaporated. The residue was purified by column chromatography on silica eluting with a gradient rising from 10% EtOAc in isohexanes to 30% EtOAc in iso-hexanes to give the title compound - E and Z isomers were separated but then re-combined (5.6 g, 100%).

25

Description 18**3-[6-(Trifluoromethyl)pyridin-3-yl]propylamine**

A solution of (E/Z)-3-[6-(trifluoromethyl)pyridin-3-yl]prop-2-enenitrile (Description 17; 5.60 g, 28.3mmol) was hydrogenated according to the method of Description 2. Following removal of the catalyst, the residue was purified by column chromatography on silica eluting with 5% MeOH in dichloromethane + 0.5% NH₄OH to give the title compound (3.5 g, 57%).

Description 19**1,2,3,4-Tetrahydronaphthalene-2-carboxamide**

To a suspension of 1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (6.08 g, 34.5 mmol) in anhydrous dichloromethane (60 ml) was added oxalyl chloride (4.52 ml, 51.8 mmol), followed by 2 drops of N,N-dimethylformamide and the resulting mixture was stirred at room temperature for 2 hours. The mixture was evaporated to dryness, toluene (50 ml) was then added and the mixture evaporated to dryness again. The residue was dissolved in anhydrous dichloromethane (100 ml) and added in one portion to dichloromethane (150 ml) which had been saturated with ammonia gas. The resulting mixture was stirred at room temperature for 48 hours. The mixture was evaporated to dryness and the residue partitioned between ethyl acetate (150 ml) and water (250 ml). The aqueous layer was further extracted with ethyl acetate (100 ml). The combined organic layers were washed with water (200 ml), brine (100 ml), then dried (Na₂SO₄) and evaporated to give the title compound (6 g, 99%) as a white solid.

Description 20**1,2,3,4-Tetrahydronaphthalen-2-ylmethylamine**

To an ice-bath cooled solution of 1,2,3,4-tetrahydronaphthalene-2-carboxamide (Description 19; 5.99 g, 34.2 mmol) in anhydrous THF (150 ml) was added in portions lithium aluminum hydride (2.6 g, 68.4 mmol). After complete addition, the mixture was heated to reflux for 3 hours then cooled in an ice bath and quenched carefully by the sequential addition of water (2.74 ml), 4N NaOH (2.74 ml) and water (8.2 ml). The resulting suspension was stirred for 10 minutes, then filtered through Celite™ and the filtrate evaporated to give the title compound (4.5 g, 81%).

Description 21**(2E/Z)-3-[4-(Trifluoromethyl)phenyl]prop-2-enenitrile**

To a solution of 4-trifluoromethyliodobenzene (7.23 g, 26.6 mmol) in anhydrous acetonitrile (130 ml) was added triethylamine (3.74 ml, 26.6 mmol), acrylonitrile (1.77 ml, 26.6 mmol), palladium (II) acetate (60 mg, 0.26 mmol), and tri-o-tolylphosphine (324 mg, 1.06 mmol) and the resulting mixture heated at reflux overnight. The cooled reaction mixture was filtered through Celite™, and

partitioned between water and ethyl acetate. The organic layer was separated and washed with brine, dried (Na_2SO_4) and evaporated. The residue was purified by column chromatography on silica eluting with 5% EtOAc in iso-hexanes to give the title compound (4.07 g, 78%).

5

Description 22

3-[4-(Trifluoromethyl)phenyl]propylamine

A solution of (*2E/Z*)-3-[4-(trifluoromethyl)phenyl]prop-2-enenitrile (Description 21; 4.06 g, 20.6 mmol) was hydrogenated according to the method of
10 Description 2. Following removal of the catalyst, the residue was purified by column chromatography on silica eluting with 4% MeOH in dichloromethane + 0.5% NH_4OH to give the title compound (3.5 g, 83%) as an oil.

Description 23

3-[3-(Trifluoromethyl)phenyl]propylamine

To an ice-bath cooled suspension of sodium hydride (1.32 g of a 60% dispersion in oil, 33 mmol) in anhydrous tetrahydrofuran (100 ml) under a nitrogen atmosphere was added dropwise a solution of diethyl cyanomethylphosphonate (5.34 ml, 33 mmol) in tetrahydrofuran (40 ml) and the resulting mixture stirred at 0 °C for 15 minutes. To this mixture was added a solution of 3-trifluoromethylbenzaldehyde (5.22 g, 30 mmol) in anhydrous tetrahydrofuran (40 ml) and the resulting mixture stirred at room temperature for 1.5 hours. Water (300 ml) was added and the mixture extracted with ethyl acetate (3 x 150 ml). The combined organic layers were washed with water (2 x 200 ml),
20 brine (150 ml) then dried (Na_2SO_4) and evaporated. The residue was taken up in a mixture of ethanol (100 ml) and ammonium hydroxide (25 ml) and
25 hydrogenated according to the method of Description 2. Purification by column chromatography on silica eluting with 5% MeOH in dichloromethane + 0.5% NH_4OH gave the title compound (1.5 g, 25%) as a yellow oil.

30

Description 24

6-(4-Fluorophenyl)nicotinamide

A mixture of 6-chloronicotinamide (5.00 g, 31.95 mmol), 4-fluorobenzene boronic acid (4.92 g, 35.14 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (1.10 g, 0.96 mmol) in a mixture of

toluene (80 ml), ethanol (12 ml) and 2M sodium carbonate (36.74 ml, 73.48 mmol) was degassed (N_2) and heated at 100 °C for 18 hours. The reaction mixture was cooled to room temperature and then filtered. The collected solid was washed with water and dried. The dried solid was taken up in methanol (100 ml) and 5 heated to reflux for 20 minutes. The mixture was then cooled to room temperature, filtered and the solid dried to give the title compound (6.25 g, 90%) as a pale grey solid.

Description 25

10 [6-(4-Fluorophenyl)pyridin-3-yl]methylamine

To an ice-bath cooled solution of sodium borohydride (5.47 g; 144.5 mmol) in anhydrous 1,4-dioxane (100 ml) was added slowly a solution of glacial acetic acid (8.27 ml, 144.5 mmol) in 1,4-dioxane (50 ml). To this mixture was added 6-(4-fluorophenyl)nicotinamide (Description 24; 6.25 g, 28.9 mmol) and the 15 resulting mixture heated at reflux for 4 hours. The cooled reaction mixture was evaporated and water (60 ml) added slowly. This mixture was extracted with dichloromethane, and the solid which appeared between the layers was removed by filtration. This solid was triturated with a mixture of dichloromethane and iso-hexanes, filtered and dried to give the title compound (510 mg, 8%) as a pale 20 green solid.

Description 26

6,7,8,9-Tetrahydro-5H-benzo[a][7]annulen-6-ylmethylamine hydrochloride

To a nitrogen flushed solution of methyl 6,7-dihydro-5H-benzo[a][7]annulene-8-25 carboxylate [*J. Org. Chem.* 1991, **56**, 6199-6205] (54.8 g, 271 mmol) in a mixture of ethyl acetate (250 ml) and glacial acetic acid (5 ml) was added 10% palladium on carbon (10 g) and the mixture was hydrogenated at 55 psi for 16 hours. The catalyst was removed by filtration, and the filtrate evaporated to dryness. The residue was dissolved in ethanol (55 ml) and 3M aqueous NaOH (165 ml, 30 495 mmol) was added, then the resulting mixture heated to reflux for 2 hours. The mixture was cooled and the ethanol removed by evaporation. The aqueous phase was washed with dichloromethane (x 3) then acidified to pH=1 with 6M HCl and extracted with dichloromethane (x 3). The combined organic phases from the acidic extraction were dried over MgSO₄, filtered and evaporated. The

residue was triturated with *tert*-butyl methyl ether, filtered and dried to give 6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxylic acid (20.6 g, 40%). This material was dissolved in dichloromethane (100 ml) containing N,N-dimethylformamide (0.5 ml) and oxalyl chloride (9.68 ml, 111 mmol) dropwise at such a rate that the internal temperature did not rise above 10 °C. The mixture was stirred at 5 °C for 30 minutes, then treated dropwise with 33% aqueous ammonium hydroxide (100 ml) whilst maintaining the temperature below 15 °C. The resulting slurry was then stirred at 10 °C for 30 minutes. The mixture was evaporated and the residue diluted with water and slurried at 0 °C for 15 minutes. The resulting white solids were filtered, washed with more water, hexanes, and dried to give 6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide (11.6 g, 55%). This material was dissolved in anhydrous THF and added dropwise over 60 minutes to a slurry of LiAlH₄ (3.24 g, 85.4 mmol) in refluxing THF. The reaction was maintained at reflux for 2 hours then cooled to 10 °C, diluted with *tert*-butyl methyl ether, and cautiously quenched by the addition of water while the temperature was maintained below 30 °C. The resulting gummy solid was removed by filtration and the phases were then separated. The aqueous phase was washed with *tert*-butyl methyl ether and the combined organic phases were dried over MgSO₄, filtered and evaporated. The residue was dissolved in isopropyl alcohol (30 ml), cooled to 0 °C and concentrated. HCl was added dropwise causing a thick slurry to form. The slurry was concentrated and the residue reconstituted with *tert*-butyl methyl ether and stirred at 40 °C for 15 minutes. The mixture was cooled to 25 °C, filtered and the resulting solids washed with *tert*-butyl methyl ether and dried to give the title compound.

Description 27

7-(Nitromethyl)-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene

A solution of 8,9-dihydro-5*H*-benzo[*a*][7]annulen-5-one (323 g, 2 mol) in nitromethane (620 ml) was treated with DBU (327 g, 2.1 mol) dropwise at such a rate that the temperature was maintained between 40 and 50 °C. After GC analysis showed reaction completion, 3M HCl (600 ml) was added and the resulting mixture was extracted with *tert*-butyl methyl ether (2 x 500 ml). The combined organic phases were treated with brine (500 ml), dried over MgSO₄,

filtered and evaporated to an oil (496 g, 90%). To 347.5g (1.58 mol) of this material dissolved in TFA (1045 ml) was added triethylsilane (583 ml, 3.65 mol) at such a rate that the temperature of the reaction mixture was maintained between 50 and 55 °C. After the addition was complete, the mixture was 5 maintained at 55 °C until GC analysis indicated reaction complete. The mixture was poured onto ice (1500 g) and water (500 ml). The resulting slurry was filtered and washed with cold hexanes (2 x 150 ml) then dried to give the title compound (139 g, 42%).

10

Description 28

6,7,8,9-Tetrahydro-5H-benzo[a][7]annulen-7-ylmethylamine hydrochloride
A mixture of 7-(nitromethyl)-6,7,8,9-tetrahydro-5H-benzo[a][7]annulene (Description 27; 48.6 g , 0.24 mol) and Ra-Ni (50 g) in ethanol (600 ml) was hydrogenated at 60 psi for 12 hours. An additional charge of Ra-Ni (50 g) was 15 added and the mixture was hydrogenated until GC analysis indicated the reaction was complete. The resulting mixture was filtered over Celite™ and washed with ethanol (200 ml). The filtrate was treated with concentrated HCl (35 ml, 0.42 mol) and concentrated under reduced pressure. The product was then slurried in *tert*-butyl methyl ether (100 ml) and cooled between 0 and 5°C, 20 filtered and washed with *tert*-butyl methyl ether (100 ml) and dried to give the title compound (21 g, 42%).

Description 29

3-(1*H*-Pyrazol-1-yl)benzylamine hydrochloride
25 To a suspension of 3-(1*H*-pyrazol-1-yl)-benzoic acid [see WO 00/21951] (104 g, 0.55 mol) in anhydrous benzene (500 ml) was added thionyl chloride (85 g, 0.715 mol) and DMF (0.5 ml). The mixture was heated at reflux for 3 hours, then evaporated under reduced pressure. The residue was dissolved in anhydrous THF (100ml) and evaporated. The residue was dissolved in anhydrous acetone 30 (600 ml), and treated with ammonium acetate (77 g, 1 mol). The mixture was heated at reflux for 12 hours, solvent was evaporated and the residue treated with cold water (2000 ml). The resulting precipitate was filtered, washed with cold water (200ml) and recrystallised from absolute ethanol (600 ml) to give 3-(1*H*-pyrazol-1-yl)benzamide (82 g, 80 %). A solution of this material (82 g,

0.44 mol) in THF was added dropwise to a solution of LiAlH₄ (25 g, 0.66 mol) in anhydrous THF (800 ml). The mixture was heated at reflux for 4 hours, cooled and quenched by the sequential addition of water (25 ml), 15% aqueous NaOH (25 ml), and water (50 ml). The inorganic by-products were filtered off and 5 washed several times with diethyl ether (overall volume 1000 ml). The combined filtrates were dried over Na₂SO₄, filtered and evaporated. The residue was dissolved in methanol (400 ml), the solution was treated with activated carbon (10 g), and the mixture was refluxed for 40 minutes, then filtered and evaporated. The residue was treated with 1N HCl in ether (1000 ml), and the precipitate 10 formed was filtered, washed with ether and dried to give the title compound (53 g, 70%).

Description 30

4-(1*H*-Pyrazol-1-yl)benzylamine hydrochloride

15 The title compound was prepared from 4-(1*H*-pyrazol-1-yl)-benzoic acid in an analogous procedure to that detailed in Description 29.

Description 31

N-Methyl-N-[4-(trifluoromethyl)benzyl]amine

20 A mixture of 4-(trifluoromethyl)benzylamine (1.0 mL, 7.02 mmol) and di-*tert*-butyl carbonate (1.68 g, 7.72 mmol) in CH₂Cl₂ (10 mL) was stirred for 1 hour. The reaction mixture was poured into saturated aqueous ammonium chloride solution, extracted with CH₂Cl₂ and the organic layers were combined, dried over MgSO₄ and concentrated *in vacuo* to give a white crystalline solid. To a solution 25 of the crude carbamate (1.00 g, 3.61 mmol) in THF (20 mL) in a room temperature water bath, was added LiAlH₄ (0.69 g, 18.1 mmol) portion-wise over 10 minutes. The reaction was then heated at reflux for 4 hours. The reaction was cooled in ice and quenched by the addition of water (1.6 mL) and NaOH (2N, 1.3 mL). The grey slurry was filtered and washed with MeOH. The MeOH was 30 removed *in vacuo* and the crude product taken up in CH₂Cl₂ and dried over MgSO₄ and concentrated *in vacuo*. Purification by flash column chromatography eluting with 5-10 % MeOH in CH₂Cl₂ plus 1 % NH₃ solution (2N in MeOH) afforded the title compound.

Description 32**1-[4-(Trifluoromethyl)phenyl]ethylamine**

To a suspension of NaCNBH₄ (0.48 g, 7.6 mmol) and 3Å molecular sieves (4 g) in MeOH (15 mL) was added NH₄OAc (6.15 g, 80 mmol) and 4-(trifluoromethyl)acetophenone (1.5 g, 8.0 mmol). The reaction was stirred at room temperature under nitrogen for 3 days. The reaction was concentrated *in vacuo* and the pH adjusted to pH 12 by the addition of aqueous NaOH (2N). The reaction was extracted with ethyl acetate and the organic layers combined, dried over MgSO₄ and the solvent removed *in vacuo*. Purification by flash column chromatography, eluting with 5 % MeOH in CH₂Cl₂ afforded the title compound.

Description 33**1,3-Diphenylpropylamine**

The title compound was prepared from 1,3-diphenylpropan-1-one in an analogous procedure to that detailed in Description 32.

Description 34**(3-Phenyl-1,2,4-oxadiazol-5-yl)methylamine hydrochloride**

A mixture of 5-chloromethyl-3-phenyl-1,2,4-oxadiazole [Synth. Commun. 1992, 22, 209] (90 g, 0.5 mol) and potassium iodide (45 g) was added as one portion to a suspension of potassium phthalimide (90 g, 0.5 mol) in DMSO (400 ml) under intensive stirring. After self-heating ceased, the mixture was heated at 130 °C for 15 minutes, cooled, and poured into water (2.5 l). The precipitate was filtered, washed with water, and dried in the air. Recrystallization from 5% DMSO in ethanol (1 l) afforded 100 g of solid. A suspension of this solid (100 g, 0.33 mol) in ethanol (2 l) was treated with glyme (0.5 l), heated to 35-40 °C, treated with hydrazine hydrate (18 g, 0.35 mol), and heated to reflux for 2 hours. The mixture was diluted with concentrated hydrochloric acid (100 ml), and refluxed for 4 hours. After cooling the mixture was filtered, extracted with ether, and evaporated. The residue was dissolved in the minimum volume of water, basified and taken up in ether (300 ml). The organic layer was separated, dried over anhydrous magnesium sulfate, and evaporated. The residue was dissolved in the minimum volume of water, neutralized with hydrochloric acid and evaporated.

The crude product was recrystallized twice from isopropanol and dried to give the title compound (21 g, 20%).

Description 35

5 (2-Benzyl-1,3-thiazol-4-yl)methylamine

2-Benzyl-4-chloromethylthiazole [Pharmazie 1972, 27, 146] (223.7 g, 1 mol) was stirred with liquid ammonia (600 ml) in an autoclave for 24 hours. The ammonia was removed and the product was distilled *in vacuo* [bp (0.02 mmHg) 141-144°C] to give the title compound (102 g, 50%).

10

Description 36

[1-(2-Methylphenyl)-1*H*-pyrazol-4-yl)methylamine

A mixture of 1-(2-tolyl)-pyrazole-4-carboxaldehyde [see US Patent No. 4,220,792] (186 g, 1 mol), hydroxylamine hydrochloride (104.2 g, 1.5 mol), and sodium acetate trihydrate (204 g) in ethanol (2 l) was refluxed for 1 hour. The mixture was cooled, diluted with water (8 l), and left overnight. The precipitate was filtered to give 1-(2-tolyl)-pyrazole oxime (186 g, 92.5 %). Tolyppyrazole oxime (50.3 g, 0.25 mol) in methanol (600 ml) and ammonia (200 ml) was hydrogenated in an autoclave in the presence of Raney nickel (10 g of ethanolic suspension) at 50°C at 70 atm. The catalyst was filtered off and washed with methanol. The filtrate was evaporated, and the residue was distilled *in vacuo* to give the title compound (43 g, 92%).

Description 37

25 3-Cyclohexylpropylamine hydrochloride

To a solution of 3-phenyl-1-propylamine (5.26 ml, 0.04 mol) in ethanol (100 ml) under nitrogen was added concentrated HCl (3 ml) and platinum oxide (0.5 g, 0.002 mol). This was placed on a Parr apparatus and hydrogenated at 50 psi for 5 days. Platinum oxide (0.5 g, 0.002 mol) was added and the mixture hydrogenated for a further 5 days. The mixture was filtered and evaporated to give the title compound (6.4 g, 98%).

Description 38**6,7,8,9-Tetrahydro-5H-benzo[a][7]annulene-7-carboxylic acid**

A solution of 7-(nitromethyl)-6,7,8,9-tetrahydro-5H-benzo[a][7]annulene (Description 27; 96 g, 0.47 mol) in THF (550 ml) was cooled to -18 °C and 5 potassium *tert*-butoxide (1.6M in THF, 263 ml, 0.42 mol) was added dropwise over 30 minutes while maintaining the temperature between -15 and -5 °C. After stirring for 10 minutes a solution of KMnO₄ (111 g, 0.7 mol) in water (900 ml) was added dropwise over 75 minutes while maintaining the temperature between -3 and 3 °C. The mixture was stirred at 0 °C until GC analysis indicated the 10 reaction was complete. *tert*-Butyl methyl ether (500 ml) was added followed by saturated aqueous NaHSO₃ (1000 ml) and the resulting mixture was stirred for 30 minutes until a milky white slurry formed. This slurry was filtered, washed with a solution of 3N NaOH (50 ml) and water (100 ml) followed by *tert*-butyl methyl ether (100 ml). The pH of the filtrate was adjusted from 8.6 to 12.5 by the 15 addition of 3N NaOH (100 ml) and 6N NaOH (40 ml). The phases were separated and to the aqueous phase was added *tert*-butyl methyl ether (500 ml). The pH of the resulting mixture was adjusted to 2 with 6N HCl (200 ml). The phases were again separated and the aqueous phase was extracted with *tert*-butyl methyl ether (2 x 300 ml). The organic phases were combined, dried over MgSO₄, filtered 20 and evaporated to give the title compound (73 g, 89%), as an off white solid.

Description 39**2-Bromo-6-fluorobenzaldehyde**

To a solution of diisopropylamine (15.7 ml 112 mmol) in anhydrous 25 tetrahydrofuran (200 ml) cooled to 0 °C was added dropwise n-butyllithium (2.5M in hexanes, 44.8 ml, 112 mmol). After complete addition the mixture was cooled to -78 °C and 3-fluorobromobenzene (19.6 g, 112 mmol) added over 10 minutes. The mixture stirred at -78 °C for 1 hour then N,N dimethylformamide (9.72 ml, 125 mmol) was added dropwise over 5 minutes. The mixture was stirred for a 30 further 10 minutes, then acetic acid (10 ml) and water (350 ml) were added. The mixture was allowed to warm to room temperature and was extracted with Et₂O (250 +150 ml). The combined extracts were washed with water (x2) 0.2N HCl, brine, dried over Na₂SO₄ and evaporated. The residue was purified by column

chromatography on silica eluting with 5% Et₂O in iso-hexanes to give the title compound (20 g, 88%) as a white solid.

Description 40

5 2-Fluoro-6-[(trimethylsilyl)ethynyl]benzaldehyde

To a solution of 2-bromo-6-fluorobenzaldehyde (Description 39; 10.0 g, 49.3 mmol) and (trimethylsilyl) acetylene (13.94 ml, 98.6 mmol) in anhydrous N,N-dimethylformamide (250 ml) under an atmosphere of nitrogen was added triethylamine (10.25 ml, 73.95 mmol), copper (I) iodide (0.94 g, 4.93 mmol) and 10 Pd(PPh₃)₂Cl₂ (1.73 g, 2.47 mmol). The mixture was degassed and stirred at room temperature overnight. The mixture was poured into water (600 ml) and extracted with ethyl acetate (3 x 200 ml). The combined organic layers were washed with water (3 x 300 ml), brine (200 ml) then dried over Na₂SO₄ and evaporated. The residue was purified by column chromatography on silica gel 15 eluting with 5% Et₂O in iso-hexanes to give the title compound (10.38 g, 95%).

Description 41

8-Fluoroisoquinoline

2-Fluoro-6-[(trimethylsilyl)ethynyl]benzaldehyde (Description 40; 10.38 g, 47.1 mmol) was dissolved in 2M ammonia in methanol (235 ml, 471 mmol) in a Parr flask and the resulting mixture heated at 80 °C with shaking on a Parr apparatus (ca. 35 psi achieved). The reaction was cooled and the solvents evaporated. The residue was purified by column chromatography on silica eluting with a gradient from neat dichloromethane to 2% methanol in 25 dichloromethane to give the title compound (4.0 g, 58 %).

Description 42

8-Fluoro-5-nitroisoquinoline

To a solution of 8-fluoroisoquinoline (Description 41; 1.24 g, 8.4mmol) in 30 concentrated sulfuric acid (10 ml) cooled to between -5 °C and 0 °C was added slowly, over 10 minutes, a solution of potassium nitrate (0.93 g, 9.24 mmol) in concentrated sulfuric acid (5 ml). The mixture was stirred at 0 °C for 30 minutes after which time TLC indicated that reaction was complete. The mixture was poured onto ice (100 g) and basified by the careful addition of 33% aqueous

ammonium hydroxide. The mixture was extracted with dichloromethane (3 x 150 ml) and the combined organic layers were washed with brine, dried over Na₂SO₄ and filtered through a 1 inch plug of silica gel. The silica gel plug was further washed with 150 ml of a 1:1 mix of ethyl acetate and iso-hexanes. The 5 combined organics were evaporated to give the title compound (1.33 g, 82%) as a brown solid.

Description 43

8-Fluoroisoquinolin-5-amine

10 To a nitrogen flushed solution of 8-fluoro-5-nitroisoquinoline (Description 42; 1.33 g, 6.9 mmol) in methanol (100 ml) was added 10% palladium on carbon (500 mg) and the resulting mixture stirred under a balloon of hydrogen for 3.5 hours. The catalyst was removed by filtration and the filtrate evaporated to dryness. The residue was purified by MPLC (Biotage Flash™ 40) eluting with 15 2% MeOH in dichloromethane to give the title compound (450 mg, 40%) as a yellow solid.

Description 44

3-Methyl-5-nitroisoquinoline

.20 3-Methylisoquinoline (2.14 g, 14.9 mmol) was added portionwise to ice-cooled concentrated H₂SO₄ (10 ml) keeping the internal temperature below 10 °C. A nitrating mixture of concentrated H₂SO₄ (2 ml) and fuming nitric acid (2 ml) was then added dropwise keeping the internal temperature below 15 °C. After stirring for 30 minutes, TLC indicated reaction was complete. The acid was 25 neutralized by adding the mixture to an excess of 4N aqueous NaOH (180 ml) with ice-cooling. The mixture was extracted with dichloromethane (2 x 150 ml), then dried (Na₂SO₄) and evaporated to give the crude product (2.69 g) as a yellow solid. Flash column chromatography using as eluant 5% methanol in dichloromethane gave a pure sample of the title compound (660 mg) and a further 30 sample (1.95 g) containing ca. 10% of the isomer 3-methyl-8-nitroisoquinoline.

Description 45**3-Methylisoquinolin-5-amine**

3-Methyl-5-nitroisoquinoline (Description 44; 660 mg, 3.51 mmol) was dissolved in MeOH (30 ml) and PtO₂ catalyst (120 mg) was added. The mixture was stirred 5 for 1 hour 45 minutes under a balloon of hydrogen, then the catalyst was filtered off, washing with more methanol. The filtrate was evaporated and purified by flash column chromatography using as eluant 5% methanol in dichloromethane to give the title compound (250 mg).

10

Description 46**1-Chloroisoquinoline**

A solution of isoquinoline-N-oxide (5.52 g, 38 mmol) in dichloromethane (50 ml) was added over 15 minutes to a solution of phosphorus oxychloride (40 ml) in dichloromethane (50 ml) at room temperature. The mixture was stirred for 1 15 hour, then heated to reflux for 2 hours. After cooling to room temperature, the mixture was poured into ice water (500 ml). The mixture was then extracted with dichloromethane (2 x 250 ml) and the combined organic layers were washed with 10% aqueous potassium carbonate solution (200 ml), brine (200 ml) then dried (Na₂SO₄) and evaporated to give the title compound (5.0 g).

20

Description 47**1-Chloro-5-nitroisoquinoline**

1-Chloroisoquinoline (Description 46; 4 g, 24.4 mmol) was nitrated according to the method of Description 44 to give the title compound (3.88 g).

25

Description 48**1-Chloroisoquinolin-5-amine**

Copper (II) acetylacetone (253 mg) was suspended in ethanol (10 ml) and sodium borohydride (366 mg) was added in one portion. The mixture was stirred 30 for 5 minutes, by which time a black suspension had appeared. A suspension of 1-chloro-5-nitroisoquinoline (Description 47; 1.01 g, 4.84 mmol) in ethanol (20 ml) was then added over 15 minutes whilst cooling in a water bath; the mixture effervesced. The mixture was stirred at room temperature for 1 hour, then more sodium borohydride (160 mg) was added and stirring continued for a further 1

hour. Water (100 ml) was added then the ethanol was evaporated and the mixture extracted with ethyl acetate (3 x 50 ml). The combined organic layers were dried (Na_2SO_4) and evaporated. Purification of the residue by flash column chromatography using 5% methanol-dichloromethane as eluant gave the title 5 compound (210 mg).

Description 49

3-Chloroisoquinoline

A mixture of 1,3-dichloroisoquinoline (9.94 g, 50.2 mmol) and hydrazine hydrate 10 (12.2 ml, 251 mmol) in ethanol (150 ml) was heated at reflux for 1.5 hours. The reaction was then cooled to room temperature and the ethanol evaporated. The residue was suspended in chloroform and manganese dioxide (20g) was added in portions over 30 minutes. Gas evolution was observed. After this had subsided, the mixture was heated to reflux for 2 hours, then filtered and evaporated. 15 Purification of the residue by flash column chromatography using dichloromethane as eluant gave the title compound (3.5 g).

Description 50

3-Chloroisoquinolin-5-amine

20 3-Chloroisoquinoline (Description 49; 3.4 g, 20.7 mmol) was nitrated according to the method of Description 44 to give crude 3-chloro-5-nitroisoquinoline (9 g). A sample (3.08 g) was added in portions over 15 minutes to a mixture of iron powder (4.2 g, 74 mmol) in water (50 ml) and 5M HCl (4 ml) at 50 °C. After the addition, the mixture was warmed to 85 °C for 2 hours, then filtered while still 25 warm to remove the iron. The filtrate was basified (4N NaOH, ca. 50 ml), then extracted with dichloromethane (3 x 150 ml). The combined organic layers were dried (Na_2SO_4) and evaporated to give the title compound (282 mg).

Description 51

6-Aminoisoquinoline

Benzophenone imine (445 μL , 2.64 mmol) was added to a mixture of 6-bromoisoquinoline (500 mg, 2.4 mmol), BINAP (60 mg, 0.1 mmol), palladium acetate (12 mg, 0.05 mmol) and cesium carbonate (1.0 g, 3.07 mmol) in THF (10 ml) at room temperature. The mixture was degassed ($\text{N}_2 \times 3$) then heated at

reflux under a nitrogen atmosphere for 16 hours. The reaction was then cooled to room temperature, partitioned between ethyl acetate (20 ml) and water (20 ml) and the aqueous phase extracted with ethyl acetate (20 ml). The combined organic phases were evaporated then re-dissolved in THF (15 ml). Hydrochloric acid (2N, aqueous, 4 ml) was added, then after stirring for 1 hour the THF was evaporated. The mixture was partitioned between ethyl acetate (20 ml) and 3M HCl (50 ml) and the aqueous phase washed with ethyl acetate (20 ml). The aqueous phase was basified (12N NaOH) then extracted with dichloromethane (3 x 50 ml). The combined organic phases were dried (Na_2SO_4) and evaporated to give the title compound (360 mg).

Description 52

N-(2-Bromobenzyl)-2,2-diethoxyacetamide

To a solution of ethyl diethoxyacetate (20.0g, 114 mmol) in ethanol (50 ml) was added a solution of sodium hydroxide (4.56 g, 114 mmol) in water (25 ml), and the resulting mixture heated at reflux for 5 hours. The mixture was evaporated to dryness, and the residue dried *in vacuo*. The resulting solid (22.75 g, 0.13 mol) was dissolved in dry ether (88 ml) and to this mixture was added thionyl chloride (13.3 g, 0.11 mol) with stirring for 10 minutes at 10 °C. The reaction mixture was heated at reflux for 30 minutes and then allowed to cool. A solution of 2-bromobenzylamine (20.73 g, 0.11 mol) in toluene (57 ml) and pyridine (34 ml) was poured into this reaction mixture with vigorous stirring. This was heated at reflux for 30 minutes and then allowed to cool. The mixture was poured into ice water and extracted with toluene (x 3). The organic extracts were combined and washed firstly with 2% HCl and then water. The solvent was evaporated and the residue purified by flash chromatography on silica gel (9:1 hexane:ethyl acetate) to give the title compound (15.6 g, 44%).

Description 53

8-Bromoisoquinolin-3-ol

N-(2-Bromobenzyl)-2,2-diethoxyacetamide (Description 52; 15.6 g, 49 mmol) was carefully added to concentrated H_2SO_4 (78 ml) with stirring at 10-20°C. The reaction mixture was stirred at room temperature for 16 hours, poured into ice water and filtered. The filtrate was neutralised with 33% aqueous ammonium

hydroxide and the resulting precipitate was filtered and dried to give the title compound (10.1 g, 91%).

Description 54

5 8-Bromo-3-methoxyisoquinoline

To a suspension of 8-bromoisoquinolin-3-ol (Description 53; 7.3 g, 0.03 mol) and silver carbonate (13.6 g, 0.05 mol) in dry DMF (380 ml) under nitrogen was added iodomethane (2.25 ml, 0.04 mol). The mixture was stirred at 50 °C for 24 hours. Further iodomethane (1 ml, 0.015 mol) was added and the mixture heated for 64 hours at 50 °C. The mixture was cooled, water (300 ml) and ethyl acetate (300 ml) were added and shaken well. The mixture was filtered through Celite™, the layers separated and the aqueous layer was extracted with ethyl acetate (3 x 50 ml). The organic layers were combined, evaporated to ~150 ml, washed twice with water and then brine. The organic extract was then evaporated to give the title compound (1.7 g, 22%).

Description 55

Methyl 3-methoxyisoquinoline-8-carboxylate

To a solution of 8-bromo-3-methoxyisoquinoline (Description 54; 1.6 g, 7.0 mmol) in anhydrous DMSO (12 ml) and methanol (8 ml) was added triethylamine (1.0 ml, 7.0 mmol), palladium acetate (30 mg, 0.1 mmol) and 1,1'-bis(diphenylphosphine)ferrocene (75 mg, 0.1 mmol). Carbon monoxide was bubbled through the mixture for 3 minutes and the reaction was then heated with stirring at 80 °C for 44 hours under a balloon of carbon monoxide. Palladium acetate (30 mg, 0.1 mmol), 1,1'-bis(diphenylphosphine)ferrocene (75 mg, 0.1 mmol), DMSO (4 ml) and methanol (6 ml) were added to the mixture and carbon monoxide was bubbled through for 3 minutes. The reaction was again heated at 80 °C under a carbon monoxide balloon for 5 hours. The mixture was allowed to cool, brine (80 ml) was added and the mixture was extracted with ethyl acetate (3 x 20 ml). The combined organic layers were washed with brine (50 ml), dried over K₂CO₃ and evaporated. The residue was chromatographed on silica gel (19:1 dichloromethane: methanol) to give the title compound (290 mg, 20%).

Description 56**3-Methoxyisoquinoline-8-carboxylic acid**

To a solution of methyl-3-methoxyisoquinoline-8-carboxylate (Description 55;

280 mg, 1 mmol) in ethanol (10 ml) was added potassium hydroxide (145 mg,

5 3 mmol) in water (6 ml). This mixture was heated at reflux for 30 minutes, cooled and the ethanol removed by evaporation. The remaining aqueous mixture was acidified with 1M HCl (3 ml) to pH 5. The solid was collected by filtration and dried in a vacuum oven to give the title compound (235 mg, 90%).

10

Description 57**Isoquinoline-8-carboxylic acid**

THF (140 ml) was added to n-butyllithium (1.6M hexanes, 70 ml, 112 mmol) at

-78 °C. A cold (-78 °C) solution of 8-bromoisoquinoline (19g, 91.3 mmol) was then

added. The reaction was stirred for 15 minutes at -78 °C, then dry CO₂ gas was

15 bubbled through the solution for 30 minutes. The cooling was then removed and the mixture warmed to 0 °C over 1 hour. The THF was removed *in vacuo*, then aqueous NaOH (2N, 300 ml) was added. The mixture was washed with *tert*-butyl methyl ether (300 ml, then 2 x 100 ml) and the combined organic layers were back extracted with aqueous NaOH (2N, 50 ml). The combined aqueous phase 20 was adjusted to pH 4.5 by the addition of 6N HCl. And the slurry cooled to 15 °C using an ice-bath. The precipitate was collected by filtration, washed with water (2 x 100 ml), isopropanol (100 ml), acetone (100 ml) and *tert*-butyl methyl ether (100 ml) to give the title compound (8.62 g).

25

Description 58**[4-(Trifluoromethyl)benzyl]isocyanate**

4-(Trifluoromethyl)phenylacetic acid (1.79 g, 8.77 mmol) was dissolved in dichloromethane (20 ml) at room temperature. Oxalyl chloride (0.92 ml,

30 10.5 mmol) was added followed by DMF (2 drops). The reaction was stirred for 4 hours, after which time effervescence had ceased. The dichloromethane and excess oxalyl chloride were then evaporated. The acid chloride was redissolved in DCM (20 ml) and poured in one go into a solution of sodium azide (0.63 g, 9.65 mmol) and tetrabutylammonium bromide (300 mg, 0.88 mmol) in water (15 ml). The mixture was stirred for 15 minutes, then the layers separated and the

aqueous layer extracted with more dichloromethane (30 ml). The combined organic layers were dried (Na_2SO_4) and evaporated to give an oil which was purified by flash column (50% dichloromethane-hexane). The acyl azide (1.54 g) so produced was dissolved in dichloromethane (20 ml) and heated at reflux to 5 quantitatively afford the title compound. The volume was adjusted to give a 0.33 M solution in dichloromethane for use in subsequent preparations.

Description 59

[4-(Trifluoromethoxy)benzyl]isocyanate

10 Prepared from 4-(trifluoromethoxy)phenylacetic acid according to the method of Description 58.

Synthesis of Ureas:

Ureas were synthesized, unless otherwise stated, using one of 2 methods. A 15 convenient procedure starts with a carboxylic acid which, on treatment with diphenylphosphoryl azide and triethylamine, undergoes a Curtius reaction. The isocyanate formed *in situ* is then trapped by addition of an amine all in one-pot. Alternatively ureas are synthesized by reacting an amine with a preformed isocyanate. Urea precursors not mentioned in Descriptions 1 to 58 are known 20 compounds.

Description 60

Representative one-pot procedure for the synthesis of ureas from a carboxylic acid and an amine

25 A mixture of carboxylic acid (0.30 mmol), diphenylphosphoryl azide (65 μl , 0.30 mmol) and triethylamine (42 μl , 0.30 mmol) in toluene (5 ml) was heated at reflux for 1 hour. To this mixture, the appropriate amine (0.30 mmol) was added and the reaction heated at reflux for 18 hours. The cooled reaction mixture was evaporated to dryness, then purified either by flash column chromatography, 30 preparative thin layer chromatography or by mass-directed HPLC. For amine hydrochloride salts, an extra equivalent of triethylamine was added.

Description 61**Representative one-pot procedure for the synthesis of ureas from an isocyanate and an amine**

An amine (0.30 mmol) and an isocyanate (0.35 mmol) were dissolved in
5 dichloromethane (10 ml), then stirred at room temperature or at reflux if
required until the starting amine had been consumed. The product was collected
by filtration, washing with a little dichloromethane. In cases where the product
did not crystallise out, the solvent was evaporated and purification was effected
either by flash column chromatography, preparative thin layer chromatography
10 or by mass-directed HPLC.

Description 62**3-(trifluoromethyl)isoquinoline**

1-Chloro-3-(trifluoromethyl)isoquinoline [see WO 01/92233] (2.0 g, 8.64 mmol)
15 was dechlorinated according to the method of Description 49 to give the title
compound (1.42 g).

Description 63**5-nitro-3-(trifluoromethyl)isoquinoline**

20 3-(trifluoromethyl)isoquinoline (Description 62; 1 g, 5.0 mmol) was nitrated
according to the method of Description 44 to give the title compound (1.1 g).

Description 64**3-(trifluoromethyl)isoquinolin-5-amine**

25 5-nitro-3-(trifluoromethyl)isoquinoline (Description 63; 1 g, 4.13 mmol) was
hydrogenated according to the method of Description 43 to give the title
compound (0.48 g).

Description 65**1-chloro-3-ethyl-5-nitroisoquinoline**

30 1-chloro-3-ethylisoquinoline [see WO 01/92233] (2.0 g, 10.4 mmol) was nitrated
according to the method of Description 42 to give the title compound (2.37 g,
96 %).

Description 66**1-chloro-3-ethylisoquinolin-5-amine**

1-chloro-3-ethyl-5-nitroisoquinoline (Description 65; 2.0 g, 8.4 mmol) was reduced according to the method of Description 50 to give the title compound (1.2 g, 69 %).

5

Description 67**1-Methyl-5-nitroisoquinoline**

Prepared by nitration of 1-methylisoquinoline according to the procedure of Description 44.

10

Description 68**1-Methylisoquinolin-5-amine**

Prepared by reduction of 1-methyl-5-nitroisoquinoline (Description 67) according to the procedure of Description 45.

15

Description 69**2,4-Difluoro-6-methoxybenzaldehyde**

To a solution of 3.5-difluoroanisole (25 g; 175 mmol) in dichloromethane (150 ml) cooled at 0°C was added titanium tetrachloride (30.7 ml; 280 mmol). To this mixture was added dropwise over 10 minutes dichloromethyl methylether (15.8 ml; 175 mmol), and after complete addition the mixture was stirred at room temperature for 1 hour. The reaction was poured onto ice/water (500 ml) and extracted with DCM (3 x 300 ml). The combined DCM layers were washed with water (500 ml), saturated NaCl (200 ml), dried over Na₂SO₄, filtered and evaporated. The residue was purified by column chromatography on silica - eluting with a gradient rising from 15% Et₂O in isohexanes rising to 30% Et₂O in isohexanes to give the title compound (11.2 g, 37%) as a white solid.

Description 70**30 2,4-Difluoro-6-hydroxybenzaldehyde**

To a solution of 2,4-difluoro-6-methoxybenzaldehyde (Description 69, 11.2 g; 77.8 mmol) in anhydrous dichloromethane (500 ml) cooled at -78°C was added boron tribromide (9.47 ml; 85.58 mmol) dropwise over 10 minutes. After complete addition the mixture was allowed to warm to room temperature and stirred

overnight. The mixture was poured onto ice/water (1 litre) and extracted with DCM (3 x 400 ml). The combined organic layers were washed with water (1 litre), saturated NaCl (500 ml), dried over Na₂SO₄, filtered and evaporated. The residue was purified by column chromatography on silica elution with 10% diethyl ether/ isohexanes to give the title compound (9.2 g, 75%) as an orange oil.

Description 71

2,4-Difluoro-6-prop-1-ynylbenzaldehyde

To an ice-bath cooled mixture of 2,4-difluoro-6-hydroxybenzaldehyde (Description 10 70, 9.20 g; 58.2 mmol) and triethylamine (8.92 ml; 64.02 mmol) in anhydrous dichloromethane (100 ml) was added dropwise over 10 minutes trifluoromethanesulfonic anhydride (11.75 ml; 69.84 mmol) and the resulting mixture stirred at room temperature for 1 hour. The mixture was washed with water (300 ml), and the aqueous phase extracted with DCM (100 ml). The 15 combined organic layers were washed with saturated NaCl (100 ml), dried over Na₂SO₄, filtered through a 1 inch plug of silica and evaporated. The residue (14.4 g; 49.6 mmol) and triethylamine (10.37 ml; 74.4 mmol) in anhydrous N,N-dimethylformamide (80 ml) contained within a large (200 ml capacity) sealed tube was cooled to -78°C and propyne gas bubbled through until the volume had 20 increased by approx 10 ml. To this mixture was added Pd(PPh₃)₂Cl₂ (1.74 g; 2.48 mmol) and CuI (449 mg; 4.96 mmol), the lid was put in place and the tube allowed to reach room temperature. The reaction was stirred for 2 hours after which TLC showed reaction was complete. The mixture was poured onto water (500 ml) and extracted with EtOAc (3 x 150 ml); the combined EtOAc layers were 25 washed with water (3 x 400 ml), saturated NaCl (150 ml), dried over Na₂SO₄, filtered through a 1 inch plug of silica and evaporated to give the title compound (8.7g, 97%).

Description 72

6,8-Difluoro-3-methylisoquinoline

A mixture of 2,4-difluoro-6-prop-1-ynylbenzaldehyde (Description 71, 8.7 g; 48.8 mmol) and 2.0M ammonia in methanol (244 ml; 488 mmol) were heated together at 80°C in a Parr apparatus (approx 35psi achieved) for 5 hours. The cooled mixture was evaporated and the residue purified by column chromatography on

silica -elution with 100% dichloromethane to give the title compound (5.2 g, 59%) as a brown solid.

Description 73

6,8-Difluoro-3-methylisoquinolin-5-amine

- 5 To an ice-bath cooled solution of 6,8-difluoro-3-methylisoquinoline (Description 72, 1.2 g; 5.35 mmol) in conc. sulfuric acid (7.5 ml) was added dropwise a mixture of fuming nitric acid (1 ml) and conc. sulfuric acid (1 ml) and the resulting mixture stirred at 0°C for 30 minutes. Poured onto ice/water (100 ml) and basified by the portionwise addition of NaHCO₃, then extracted with EtOAc (3 x 100 ml). The combined EtOAc layers were flushed with nitrogen and a spatula end of 5% palladium on carbon added and the reaction was stirred under a balloon of hydrogen for 3 hours. The catalyst was removed by filtration and the filtrate evaporated. The residue was purified by column chromatography on silica elution with 1% MeOH in DCM + 0.5% NH₄OH to give the title compound 15 (930 mg, 89%).

Description 74

3-Methyl-7-(trifluoromethyl)isoquinolin-5-amine

- Prepared using 2-hydroxy-5-trifluoromethylbenzaldehyde [see WO-A-9962902] in 20 place of 2,4-difluoro-6-hydroxybenzaldehyde according to the procedures of Descriptions 71, 72, and 73 respectively.

Description 75

2-Fluoro-6-prop-1-ynylbenzaldehyde

- 25 A mixture of 2-bromo-6-fluorobenzaldehyde [see *Tetrahedron Letters* (1992), 33(49), 7499-7502] (4.0 g; 19.7 mmol) and triethylamine (4.12 ml; 29.5 mmol) in anhydrous N,N-dimethylformamide (75 ml) contained within a large (200 ml capacity) sealed tube was cooled to -78°C and propyne gas bubbled through until the volume had increased by approx 10 ml. To this mixture was added 30 Pd(PPh₃)₂Cl₂ (0.69 g; 0.99 mmol) and CuI (180 mg; 1.97 mmol), the lid was put in place and the tube allowed to reach room temperature and stir for 4 hours after which TLC showed the reaction was complete. The mixture was poured onto water (500 ml) and extracted with EtOAc (3 x 150 ml). The combined EtOAc layers were washed with water (3 x 400 ml), saturated NaCl (150 ml), dried over

Na₂SO₄, filtered through a 1 inch plug of silica and evaporated to give the title compound (3.2 g, 100%).

Description 76

5 8-Fluoro-3-methylisoquinolin-5-amine

Prepared using 2-fluoro-6-prop-1-ynylbenzaldehyde (Description 75) in place of 2,4-difluoro-6-prop-1-ynylbenzaldehyde according to the procedures of Descriptions 72 and 73 respectively.

10

Description 77

(2-Bromo-4-fluorophenyl)methanol

To a solution of 2-bromo-4-fluorobenzoic acid (20g; 91mmol) in anhydrous THF (300 ml) at -10°C was added dropwise borane tetrahydrofuran complex (1.0M soln in THF) (136.5ml; 136.5mmol). After complete addition the reaction was allowed 15 to stir at room temperature for 4 hours. The reaction was quenched by the dropwise addition of water (20 ml). To the mixture was added saturated K₂CO₃ (200 ml) and water (300 ml). The organic layer was separated and the aqueous extracted with Et₂O (2 x 300 ml). The combined organics were washed with water (2 x 500 ml), saturated NaCl (200 ml), dried over Na₂SO₄, filtered and 20 evaporated to give the title compound (18g, 96%) as a white solid.

Description 78

2-Bromo-4-fluorobenzaldehyde

To a -78°C cooled solution of oxalyl chloride (8.43 ml; 96.58 mmol) in anhydrous dichloromethane (300 ml) was added dropwise dimethyl sulfoxide (13.71 ml; 193.16 mmol). The mixture was stirred at -78°C for 5 minutes then a solution of (2-bromo-4-fluorophenyl)methanol (Description 77, 18 g; 87.8 mmol) in anhydrous dichloromethane (150 ml) was added slowly. The resulting mixture was stirred at -78°C for 15 minutes then triethylamine (36.71 ml; 263.4 mmol) was added and 30 the mixture allowed to warm to room temperature over 1 hour. The mixture was washed with water (2 x 500 ml), saturated NaCl (200 ml), dried over Na₂SO₄, filtered through a 2 inch plug of silica gel and evaporated to give the title compound (16 g, 89%) as a white solid.

Description 79

6-Fluoro-3-methylisoquinolin-5-amine

Prepared using 2-bromo-4-fluorobenzaldehyde (Description 78) in place of 2-bromo-6-fluorobenzaldehyde according to the procedures of Descriptions 75, 72, 5 and 73 respectively.

Description 80

2-Hydroxy-5-methoxy-3-nitrobenzaldehyde

10 To a solution of 5-methoxysalicylaldehyde (22.52 g ; 148 mmol) in acetic acid (120 ml) was added dropwise over 1 hour a mixture of fuming nitric acid (7.1 ml) in acetic acid (25 ml). After complete addition the mixture was stirred at room temperature for 5 hours. The precipitate was removed by filtration, washed with ethanol and dried to give the title compound (20.3 g, 69%) as a bright yellow
15 solid.

Description 81

2-Formyl-4-methoxy-6-nitrophenyl trifluoromethanesulfonate

To an ice-bath cooled solution of 2-hydroxy-5-methoxy-3-nitrobenzaldehyde 20 (Description 80, 11.00 g; 55.8 mmol) and triethylamine (10.11 ml; 72.54 mmol) in anhydrous dichloromethane (150 ml) was added slowly trifluoromethane sulfonic anhydride (11.73 ml ; 69.75 mmol) and the resulting mixture stirred at room temperature for 1.5 hours. The mixture was washed with water (250 ml), dried over Na₂SO₄, filtered through a 1.5 inch plug of silica and evaporated to give the 25 title compound (17 g, 92%) as a yellow oil.

Description 82

7-Methoxyisoquinolin-5-amine

Prepared using 2-formyl-4-methoxy-6-nitrophenyl trifluoromethanesulfonate 30 (Description 81) in place of 2-bromo-6-fluorobenzaldehyde according to the procedures of Descriptions 40, 41, and 43 respectively.

Description 83**1,3-Dimethylisoquinolin-5-amine**

Prepared using 1,3-dimethylisoquinoline (*Chem Lett.* 1983, 5, 791) in place of 3-methylisoquinoline according to the procedures of Descriptions 44 and 43
5 respectively.

Description 84**4-Chloro-2-formyl-6-nitrophenyl trifluoromethanesulfonate**

10 Prepared using 5-chlorosalicylaldehyde in place of 5-methoxysalicylaldehyde according to the procedures of Descriptions 80 and 81 respectively.

Description 85**7-Chloro-3-methyl-5-nitroisoquinoline**

15 Prepared using 4-chloro-2-formyl-6-nitrophenyl trifluoromethanesulfonate (Description 84) in place of 2-bromo-6-fluorobenzaldehyde according to the procedures of Descriptions 75 and 72 respectively.

Description 86**7-Chloro-3-methylisoquinolin-5-amine**

To a nitrogen flushed solution of 7-chloro-3-methyl-5-nitroisoquinoline (Description 85; 300 mg, 1.35 mmol) in methanol (30 ml) was added a spatula end of Palladium 5% on calcium carbonate poisoned with lead (Lindlar catalyst), and the resulting mixture stirred under a balloon of hydrogen overnight. The catalyst 25 was removed by filtration and the filtrate evaporated. The residue was dissolved in methanol (20 ml) and silica gel (2 g) added and evaporated to dryness. Loaded onto a silica gel column and eluted with 1% MeOH in DCM + 0.5% NH₄OH to give the title compound (190 mg, 73%) as an orange solid.

30

Description 87**7-Chloroisooquinolin-5-amine**

Prepared using 4-chloro-2-formyl-6-nitrophenyl trifluoromethanesulfonate (Description 84) in place of 2-bromo-6-fluorobenzaldehyde according to the procedures of Descriptions 40, 41 and 86 respectively.

Description 88**8-Fluoro-3-methoxyisoquinoline-5-carboxylic acid**

Prepared using 5-bromo-2-fluorobenzylamine in place of 2-bromobenzylamine
5 according to the procedures of Descriptions 52, 53, 54, 55, and 56 respectively.

Description 89**6-Fluoroisoquinolin-5-amine**

Prepared using 2-bromo-4-fluorobenzaldehyde (Description 78) in place of 2-
10 bromo-6-fluorobenzaldehyde according to the procedures of Descriptions 40, 41,
44 and 43 respectively.

Description 90**7-Fluoroisoquinolin-5-amine**

15 Prepared using 2-bromo-5-fluorobenzoic acid in place of 2-bromo-4-fluorobenzoic
acid according to the procedures of Descriptions 77, 78, 40, 41, 44 and 43
respectively.

Description 91**20 4-Methylisoquinolin-5-amine**

Prepared using 4-methylisoquinoline (*Tet. Lett.* 1987, 28(44), 5291) in place of 3-
methylisoquinoline according to the procedures of Descriptions 44 and 43
respectively.

25

Description 92**8-(Trifluoromethyl)isoquinoline**

A mixture of 2-trifluoromethylbenzaldehyde (15 g; 86 mmol) and
aminoacetaldehyde dimethylacetal (9.37 ml; 86mmol) in toluene (75 ml) was
heated at reflux under Dean/Stark conditions for 2 hours. The cooled reaction
30 mixture was evaporated to dryness and the residue added dropwise to conc.
sulfuric acid (200 ml) at 140°C ; after complete addition the heating was
continued for 30 mins then the warm mixture was poured over ice. The mixture
was filtered and the filtrate basified by the addition of 4N NaOH with cooling.
The basic solution was extracted with Et₂O (x 3), the combined Et₂O layers were

dried over Na_2SO_4 , filtered and evaporated. The residue was dissolved in DCM and filtered through a short plug of silica and evaporated to give 1.2g (Yield 7%).

Description 93

5 8-(Trifluoromethyl)isoquinolin-5-amine

Prepared using 8-(trifluoromethyl)isoquinoline (Description 92) in place of 3-methylisoquinoline according to the procedures of Descriptions 44 and 43 respectively.

10

Description 94

2-Methoxy-4-(trifluoromethyl)benzonitrile

To a solution of 2-nitro-4-(trifluoromethyl)benzonitrile (22.48 g, 104 mmol) in anhydrous methanol (110 ml) was added dropwise 25% sodium methoxide in methanol (24.72 ml, 114.4 mmol), and the resulting mixture stirred at room temperature for 1 hour. Water (110 ml) was added and the resulting solids collected by filtration. The solids were dissolved in DCM (150 ml), washed with sat NaCl (75 ml), dried over Na_2SO_4 , filtered and evaporated to give the title compound (19 g, 91%) as a white solid.

20

Description 95

2-Methoxy-4-(trifluoromethyl)benzoic acid

To a solution of 2-methoxy-4-(trifluoromethyl)benzonitrile (Description 94; 19 g, 94.4 mmol) in ethanol (150 ml) was added a solution of potassium hydroxide (26.43 g ; 472 mmol) in water (100 ml) and the resulting mixture heated at reflux overnight. The mixture was cooled and the ethanol removed by evaporation, the remaining aqueous phase was extracted with diethyl ether then acidified with 5N HCl. The acidic aqueous phase was then extracted with EtOAc (3 x 200 ml) and the combined organic layers washed with water, sat NaCl, dried over Na_2SO_4 , filtered and evaporated to give the title compound (19.91 g, 95%).

Description 96

2-Methoxy-4-(trifluoromethyl)benzaldehyde

Prepared using 2-methoxy-4-(trifluoromethyl)benzoic acid (Description 95) in place of 2-bromo-4-fluorobenzoic acid according to the procedures of Descriptions 5 77 and 78 respectively.

Description 97

2-hydroxy-4-(trifluoromethyl)benzaldehyde

A mixture of 2-methoxy-4-trifluoromethyl benzaldehyde (Description 96; 18 g, 88 10 mmol) and lithium chloride (11.19 g ; 264 mmol) in anhydrous N,N-dimethylformamide (100 ml) was heated at reflux for 3 hours. The mixture was cooled and poured into water (200 ml), then acidified by the addition of 1N HCl. The mixture was extracted with ether (3 x 200 ml) then the combined ether layers washed with water (2 x 500 ml), sat NaCl (100 ml), dried over Na₂SO₄, 15 filtered and evaporated to give the title compound (16.25 g, 97%).

Description 98

6-(Trifluoromethyl)isoquinolin-5-amine

Prepared using 2-hydroxy-4-(trifluoromethyl)benzaldehyde (Description 97) in 20 place of 2-hydroxy-5-methoxy-3-nitrobenzaldehyde according to the procedures of Descriptions 81, 40, 41, 44, and 43 respectively.

Description 99

7-(Trifluoromethyl)isoquinolin-5-amine

25 Prepared using 2-hydroxy-5-(trifluoromethyl)benzaldehyde [see WO-A-9962902] in place of 2-hydroxy-5-methoxy-3-nitrobenzaldehyde according to the procedures of Descriptions 81, 40, 41, 44, and 43 respectively.

Description 100

30

5-Fluoro-1-methylindene

A solution of 5-fluoro-1-indanone (25 g, 0.17 mol) in dry THF (100 ml) was added dropwise to a solution of methyl magnesium bromide (70 ml of 3N in diethyl ether, 0.21 mol) in dry THF (50 ml) at 0°C. The mixture was stirred at RT

overnight. The reaction mixture was quenched with aq. HCl to pH 1 and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with brine, dried over MgSO₄ and evaporated to give the title compound as an oil (22.3 g, 91%).

5

Description 101

6-Fluoro-1-methylisoquinoline

A solution of 5-fluoro-1-methylindene (Description 100, 22.3 g, 0.15 mol) in methanol (350 ml) was cooled to -78°C and ozonised for 9.5 h. The reaction mixture was purged with nitrogen and removed from the cooling bath. Sodium bicarbonate (20 g) and dimethyl sulfide (30 ml) were added and the reaction mixture stirred at RT for 6 hr. Ammonium hydroxide (200 ml) was then added and the reaction mixture stirred at RT for 48 hr. The resulting mixture was poured into water (1 litre) and extracted with dichloromethane (3 x 400 ml). The organic extracts were combined, washed with water and brine, dried over MgSO₄ and evaporated. The residue was purified by flash column chromatography using an eluant system of 1% MeOH/ 99% DCM to give the title compound (1.4 g, 5.8%).

20

Description 102

6-Fluoro-1-methyl-5-nitroisoquinoline

Prepared by nitration of 6-fluoro-1-methylisoquinoline (Description 101) according to the procedure of Description 44 to give the title compound (530 mg, 25 30%).

Description 103

6-Fluoro-1-methylisoquinolin-5-amine

30 Prepared by reduction of 6-fluoro-1-methyl-5-nitroisoquinoline (Description 102) according to the procedure of Description 43 to give the title compound (435 mg, 96%).

Description 1045-Nitroisoquinoline-1-carboxylic acid

Isoquinoline-1-carboxylic acid (3.98 g, 23.0 mmol) was dissolved in conc. sulfuric acid (16 ml) at 0 °C. A mixture of conc. sulfuric acid (5 ml) and fuming nitric acid (5 ml) was added over 10 min. and the reaction stirred for a further 1h at 0 °C, then poured into ice-water (400 ml). The solid was collected by filtration, then washed with water (100 ml), ethanol (100 ml) and ether (100 ml), then dried under vacuum to give the title compound (4.1 g, 82%).

10

Description 105Methyl 5-nitroisoquinoline-1-carboxylate

Potassium carbonate (23 g, 167 mmol) was added to a solution of 5-nitroisoquinoline-1-carboxylic acid (Description 104, 2.7 g, 12.4 mmol) in N,N-dimethylformamide (50 ml) at room temperature. Iodomethane (1.0 ml, 16.1 mmol) was then added and the reaction stirred at room temperature for 20 h. Water (300ml) was added and the mixture was extracted with ethyl acetate (2 x 200 ml). The combined organic phases were washed with water (2 x 100 ml), brine (100 ml) then dried (Na_2SO_4) and evaporated. Purification of the residue by column chromatography eluting with ethyl acetate - isohexane (7:13 increasing to 1:1) gave the title compound (558 mg, 19%).

Description 106

25

Methyl 5-aminoisoquinoline-1-carboxylate

Prepared by reduction of methyl 5-nitroisoquinoline-1-carboxylate (Description 105) according to the procedure of Description 45.

30

Description 107Methyl-5-aminoisoquinoline-3-carboxylate

Prepared using isoquinoline-3-carboxylic acid in place of isoquinoline-1-carboxylic acid according to the procedures of Descriptions 104, 105 and 106 respectively.

35

Description 1083-Chloro-5-nitroisoquinoline

3-Chloroisoquinoline (Description 49; 3.4 g, 20.7 mmol) was nitrated according to
5 the method of Description 44. After addition of the base, the solid was filtered off
to give crude 3-chloro-5-nitroisoquinoline (9 g). A sample (6.8 g) was partitioned
between ethyl acetate and 10% aqueous K₂CO₃ solution (200 ml). The organic
layer was extracted with more ethyl acetate (100 ml) and the combined organic
phases dried (Na₂SO₄) and evaporated to give the title compound (2.10 g, 64%).

10

Description 1093-(Dimethylamino)isoquinolin-5-amine

3-Chloro-5-nitroisoquinoline (Description 108, 160 mg, 0.767 mmol) was dissolved
15 in 33% ethanolic dimethylamine (6 ml) and the mixture then heated in a sealed
tube at 100 °C for 2.5 h. After cooling to room temperature the solvent and excess
dimethylamine was evaporated and the residue reduced according to the
procedure of Description 45 to give the title compound (85 mg, 59%).

20

Description 1102-(4-Hydroxybut-1-ynyl)benzaldehyde

To a solution of 2-bromobenzaldehyde (10 g, 54 mmol) in anhydrous N,N-
dimethylformamide (150 ml) was added 3-butyn-1-ol (6.13 ml, 81 mmol) and
25 triethylamine (11.3 ml, 81 mmol), followed by copper (I) iodide (490 mg, 5.4
mmol) and Pd(PPh₃)₂Cl₂ (1.9 g, 2.7 mmol), and the mixture degassed three times
and stirred at room temperature overnight. The mixture was poured into water
(600 ml) and extracted with EtOAc (3 x 150 ml); the combined EtOAc layers were
washed with water (2 x 250 ml), sat NaCl (100 ml), then dried over Na₂SO₄,
30 filtered and evaporated. The residue was purified by column chromatography on
silica eluting with 50% Et₂O in isohexanes to give the title compound (8.5 g, 90%)
as an orange oil.

Description 111

3-(2-Hydroxyethyl)isoquinoline

A solution of 2-(4-hydroxybut-1-ynyl)benzaldehyde (Description 110; 8.50 g, 48.8 mmol) in 2M methanolic ammonia (122 ml, 244 mmol) contained in a Parr flask was heated at 80°C for 2 hours (approx 35 psi achieved). The cooled mixture was evaporated and the residue purified by column chromatography on silica elution with a gradient rising from 1% MeOH in DCM + 0.5% NH₄OH to 5% MeOH in DCM + 0.5% NH₄OH to give the title compound (6.2 g, 73%) as a beige solid.

10

Description 112

3-(2-Azidoethyl)isoquinoline

To a ice-bath cooled solution of 3-(2-hydroxyethyl)isoquinoline (Description 111; 4.85 g, 28 mmol) and triethylamine (5.07 ml, 36.4 mmol) in anhydrous dichloromethane (100 ml) was added slowly methanesulfonyl chloride (2.49 ml, 32.2 mmol), and the resulting mixture stirred at room temperature for 1 hour. The mixture was washed with water (200 ml), sat NaCl (100 ml), dried over Na₂SO₄, filtered and evaporated. The residue was dissolved in anhydrous N,N-dimethylformamide (100 ml) and sodium azide (2.00 g, 30.8 mmol) added and the resulting mixture stirred at room temperature for 4 days. The mixture was poured into water (400 ml), and extracted with EtOAc (3 x 100 ml). The combined EtOAc layers were washed with water (3 x 200 ml), saturated aqueous NaCl (100 ml), dried over Na₂SO₄, filtered and evaporated to give the title compound (5.6 g, 100%).

Description 113

3-(2-Aminoethyl)isoquinoline

30 To a solution of 3-(2-azidoethyl)isoquinoline (Description 112; 5.6 g, 28.3 mmol) in anhydrous tetrahydrofuran (50 ml) was added triphenylphosphine (14.85 g, 56.6 mmol) and water (0.509 ml, 28.3 mmol), and the resulting mixture stirred at room temperature overnight. The mixture was loaded directly onto a Bond-elut SCX cartridge and eluted with methanol until TLC indicated complete elution of

triphenylphosphine. The product was then eluted with 2.0M ammonia in methanol. The basic fractions were collected and evaporated to give the title compound (2.7 g, 55%).

5

Description 114

Ethyl 2-isoquinolin-3-ylethylcarbamate

To an ice-bath cooled solution of 3-(2-aminoethyl)isoquinoline (Description 113; 2.70 g, 15.7 mmol) and triethylamine (2.84 ml, 20.41 mmol) in anhydrous dichloromethane (75 ml) was added slowly ethyl chloroformate (1.65 ml, 17.27 mmol) and the resulting mixture stirred at room temperature for 1 hour. The mixture was washed with water, sat NaCl, dried over Na₂SO₄, filtered and evaporated. The residue was purified by column chromatography on silica elution with a gradient rising from DCM to 2% MeOH in DCM + 0.5% NH₄OH to give the title compound (2.27 g, 59%).

Description 115

Ethyl 2-(5-aminoisoquinolin-3-yl)ethylcarbamate

20 Prepared using ethyl 2-isoquinolin-3-ylethylcarbamate (Description 114) in place of 3-methylisoquinoline according to the procedures of Descriptions 44 and 43 respectively.

Description 116

25

tert-Butyl 2-(5-aminoisoquinolin-3-yl)ethylcarbamate

To a solution of potassium hydroxide (450 mg ; 8.02 mmol) in ethanol was added ethyl 2-(5-aminoisoquinolin-3-yl)ethylcarbamate (Description 115; 1.04 g, 2.6 mmol), and the resulting mixture heated at reflux until HPLC indicated the reaction was complete (approx 5 days). The mixture was cooled and loaded directly onto a Bond-elut SCX cartridge. The cartridge was washed with methanol, and the product then eluted with 2M ammonia in methanol. The basic fractions were evaporated and the residue dissolved in dichloromethane (15 ml). Di-tert butyl dicarbonate (830 mg, 3.8 mmol) was added and the resulting

mixture stirred at room temperature for 1 hour, then evaporated to dryness to give the title compound (1.1g, 100%).

Description 117

5

Isoquinolin-7-yl trifluoromethanesulfonate

7-Hydroxyisoquinoline (1.4 g, 9.6 mmol) and triethylamine (1.5 ml, 10.6 mmol) were added to ether (50 ml) under a nitrogen atmosphere at 0 °C. Trifluoromethylsulfonic anhydride (1.8 ml, 10.6 mmol) was added dropwise and 10 the mixture then warmed to room temperature for 3h. The layers were separated and the lower layer extracted with ether (2 x 100 ml). The combined organics were then dried (Na_2SO_4) and evaporated to give the title compound as a brown oil (1.04 g).

15

Description 118

2-(Trifluoromethyl)pyrimidine-5-carboxylic acid

To a solution of methyl 2-trifluoromethyl pyrimidine-5-carboxylate [see WO-A-0066567] (5 g, 22.7 mmol) in methanol (100 ml) was added a solution of 20 lithium hydroxide (1.09 g, 45.4 mmol) and the resulting mixture stirred at room temperature overnight. The methanol was removed by evaporation and the residue further diluted with water (50 ml). Extracted with EtOAc (x 3) and the aqueous phase was then acidified by the addition of c.HCl. The precipitate was extracted into EtOAc (x3) and the combined organic layers washed with sat NaCl, 25 dried over Na_2SO_4 , filtered and evaporated to give the title compound (2.0 g, 46%).

Description 119

30

5-(Hydroxymethyl)-2-(trifluoromethyl)pyrimidine

To an ice-bath cooled solution of 2-(trifluoromethyl)pyrimidine-5-carboxylic acid (Description 118; 2 g, 10.4 mmol) in anhydrous tetrahydrofuran (100 ml) was added dropwise borane tetrahydrofuran complex [1.0M solution in THF] (15.6 ml, 15.6 mmol), after complete addition the mixture was stirred at room temperature

for 90 mins. The reaction was quenched by the careful addition of water (2 ml), followed by saturated aqueous K₂CO₃. The organic layer was separated, and the aqueous phase extracted with Et₂O. The combined organics were then washed with water, saturated NaCl, dried over Na₂SO₄, filtered and evaporated to give
5 the title compound (580 mg, 31%).

Description 120

5-Azidomethyl-2-(trifluoromethyl)pyrimidine

10 To a solution of 5-(hydroxymethyl)-2-(trifluoromethyl)pyrimidine (Description 119; 580 mg, 3.26 mmol) and triethylamine (0.55 ml, 3.91 mmol) in anhydrous dichloromethane (15 ml) cooled in an ice-bath was added dropwise methanesulfonyl chloride (0.28 ml, 3.59 mmol), and the resulting mixture stirred at room temperature for 1 hour. The mixture was washed with water and sat
15 NaCl, dried over Na₂SO₄, filtered and evaporated. The residue was dissolved in anhydrous N,N-dimethylformamide (15 ml), sodium azide (233 mg, 3.59 mmol) was added and the resulting mixture stirred at room temperature overnight. The mixture was poured into water (100 ml) and extracted with EtOAc (3 x 15 ml). The combined EtOAc layers were washed with water (2 x 50 ml), saturated NaCl
20 (25 ml), dried over Na₂SO₄, filtered and evaporated to give the title compound (660 mg, 100%).

Description 121

5-(Aminomethyl)-2-(trifluoromethyl)pyrimidine

25 To a solution of 5-(azidomethyl)-2-(trifluoromethyl)pyrimidine (Description 120; 660mg, 3.26mmol) in anhydrous THF (10 ml) was added triphenylphosphine (1.71g, 6.52mmol) and water (0.059ml, 3.26mmol) and the resulting mixture stirred at room temperature overnight. The mixture was evaporated and the
30 residue purified by column chromatography on silica elution with 5% MeOH in DCM + 0.5% NH₄OH to give the title compound (320 mg, 55%) as a pale yellow solid.

Description 122**4-(Morpholin-4-ylmethyl)benzonitrile**

To a solution of 4-cyanobenzylbromide (1.0 g, 5.1 mmol) in MeCN (10 ml) was
5 added morpholine (0.44 g, 0.44 ml, 5.1 mmol) and the reaction was stirred at room temperature for 1 h. The precipitate was filtered off and partitioned between CH₂Cl₂ and NaOH (2M). The organic layer was separated, dried over MgSO₄ and dried to give the desired nitrile (0.70 g, 68 %).

10

Description 123**4-(Morpholin-4-ylmethyl)benzylamine**

To a suspension of 4-(morpholin-4-ylmethyl)benzonitrile (Description 122, 0.5 g, 2.5 mmol) in THF (7 mL) at 0°C was added dropwise a solution of LiAlH₄ (1.0 M in THF, 2.5 ml, 2.5 mmol). The reaction was stirred at 0°C for 1h. Additional LiAlH₄ (1.0 M in THF, 1.0 ml, 1.0 mmol) was added and the reaction stirred for an additional 30 min. The reaction was quenched by the addition of water (0.13 mL) followed by 15 % NaOH solution (0.13 ml) and stirred vigorously for 1 h. The reaction was filtered through celite, evaporated and azeotroped twice with
20 toluene. The amine was used crude.

Description 124**2-(2-Morpholin-4-ylethoxy)-4-(trifluoromethyl)benzonitrile**

25 To a solution of 2-nitro-4-trifluoromethyl benzonitrile (0.5 g, 2.3 mmol) and 2-morpholin-4-yl-ethanol (0.37 g, 0.34 ml, 2.8 mmol) in DMF (4 ml) was added dropwise a solution of KOH (0.23 g, 4.1 mmol) in water (1.5 ml). After 10 min the reaction was poured into ice water and the white crystalline product collected by filtration, washed with water and dried (0.5 g, 72 %).

30

Description 125

2-(2-Morpholin-4-ylethoxy)-4-(trifluoromethyl)benzylamine

To a solution of 2-(2-morpholin-4-ylethoxy)-4-(trifluoromethyl)benzonitrile

5 (Description 124, 0.5 g, 1.67 mmol) in ethanol (30 ml) was added aqueous ammonia (33 % aq soln, 5 ml) and a slurry of 10 % Pd/C catalyst in water. The reaction was hydrogenated at 43 psi. After 45 min the reaction was complete. The catalyst was filtered off, the reaction condensed and the product azeotroped with toluene to give the desired amine (0.49 g, 96 %).

10

Description 126

Isoquinoline-5-carbonyl azide

Isoquinoline-5-carboxylic acid monohydrate (5.00 g, 26.2 mmol) was suspended in

15 dichloromethane (200 ml) and N,N-dimethylformamide (5 drops) added. Oxalyl chloride (4.57 ml, 52 mmol) was then added and the reaction stirred for 7h. The solvent and excess oxalyl chloride was then evaporated and the residue taken up in dichloromethane (200 ml). A solution of sodium azide (2.1 g, 32.3 mmol) and tetra-n-butylammonium bromide (850 mg) in water (50 ml) was then added in
20 one portion and the mixture stirred for 20 min. The layers were separated and the aqueous phase extracted with more dichloromethane (100 ml). The combined organic phases were evaporated and the residue purified by flash column chromatography (eluant ethyl acetate – dichloromethane (1:4)) to give the title compound as a yellow solid (2.27 g, 44 %).

25

Example 1

N-Benzyl-N'-isoquinolin-5-ylurea

Prepared from 5-aminoisoquinoline and benzyl isocyanate according to the procedure of Description 61. m/z (ES $^+$) 278 ($M + H$) $^+$.

30

Examples 2 to 16 were prepared according to the procedure of Description 60.

Example 2N-(1,1'-Biphenyl-4-ylmethyl)-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid [see WO 95/09843] and 4-phenylbenzylamine. m/z (ES⁺) 354 ($M + H$)⁺.

5

Example 3N-(1,1'-Biphenyl-3-ylmethyl)-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 3-phenylbenzylamine. m/z (ES⁺) 354 ($M + H$)⁺.

10

Example 4N-Isoquinolin-5-yl-N'-(3-phenylpropyl)urea

Prepared from isoquinoline-5-carboxylic acid and 3-phenylpropylamine. m/z (ES⁺) 306 ($M + H$)⁺.

15

Example 5N-Isoquinolin-5-yl-N'-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)urea

Prepared from isoquinoline-5-carboxylic acid and 1,2,3,4-tetrahydronaphthalen-2-ylmethylamine (Description 20). m/z (ES⁺) 332 ($M + H$)⁺.

20

Example 6N-[2-(4-Chlorophenyl)ethyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 2-(4-chlorophenyl)ethylamine. m/z (ES⁺) 326 ($M + H$)⁺.

25

Example 7N-[3,5-bis(Trifluoromethyl)benzyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 3,5-bis(trifluoromethyl)benzylamine. m/z (ES⁺) 414 ($M + H$)⁺.

30

Example 8N-[3-(3,4-dimethylphenyl)propyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 3-(3,4-dimethylphenyl)-propylamine. m/z (ES $^+$) 334 ($M + H$) $^+$.

5

Example 9N-(4-tert-Butylbenzyl)-N'-isoquinolin-8-ylurea

Prepared from isoquinoline-8-carboxylic acid and 4-*tert*-butylbenzylamine. m/z (ES $^+$) 334 ($M + H$) $^+$.

10

Example 10N-(4-tert-Butylbenzyl)-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 4-*tert*-butylbenzylamine. m/z (ES $^+$) 334 ($M + H$) $^+$.

15

Example 11N-(4-tert-Butylbenzyl)-N'-quinolin-5-ylurea

Prepared from quinoline-5-carboxylic acid [see WO 95/09843] and 4-*tert*-butylbenzylamine. m/z (ES $^+$) 334 ($M + H$) $^+$.

20

Example 12N-(3-tert-Butylbenzyl)-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 3-*tert*-butylbenzylamine (Description 9). m/z (ES $^+$) 334 ($M + H$) $^+$.

25

Example 13N-[2-(4-tert-Butylphenyl)ethyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 2-(4-*tert*-butylphenyl)ethylamine. m/z (ES $^+$) 348 ($M + H$) $^+$.

30

Example 14N-Isoquinolin-5-yl-N-[4-(trifluoromethyl)benzyl]urea

Prepared from isoquinoline-5-carboxylic acid and 4-trifluoromethylbenzylamine.

m/z (ES⁺) 346 (M + H)⁺.

5

Example 15N-Isoquinolin-5-yl-N-[3-(trifluoromethyl)benzyl]urea

Prepared from isoquinoline-5-carboxylic acid and 3-trifluoromethylbenzylamine.

m/z (ES⁺) 346 (M + H)⁺.

10

Example 16N-Isoquinolin-5-yl-N-[2-[4-(trifluoromethyl)phenyl]ethyl]urea

Prepared from isoquinoline-5-carboxylic acid and

2-[4-(trifluoromethyl)phenyl]ethylamine (Description 6). *m/z* (ES⁺) 360 (M + H)⁺.

15

Example 17N-(2-Oxidoisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

To a suspension of *N*-isoquinolin-5-yl-*N*-[4-(trifluoromethyl)benzyl]urea

(Example 14; 100 mg, 0.29 mmol) in chloroform (25 ml) was added Oxone

20 (541 mg, 0.87 mmol), followed by wet alumina Grade III (1g), and the resulting suspension heated at reflux for 60 minutes. Whilst the mixture was still hot it was filtered to remove alumina and Oxone, the solids were washed with more chloroform, then methanol, and the filtrate evaporated to dryness. The residue was purified by preparative TLC eluting with 10% MeOH in dichloromethane +

25 0.5% NH₄OH, and the product triturated with a mixture of dichloromethane/isohexanes, filtered and dried to give the title compound (11 mg, 10%) as a white solid. *m/z* (ES⁺) 362 (M + H)⁺.

Examples 18 to 51 were prepared according to the procedure of Description 60.

30

Example 18N-Isoquinolin-5-yl-N-[2-[3-(trifluoromethyl)phenyl]ethyl]urea

Prepared from isoquinoline-5-carboxylic acid and

2-[3-(trifluoromethyl)phenyl]ethylamine. *m/z* (ES⁺) 360 (M + H)⁺.

Example 19*N*-Isoquinolin-5-yl-*N*^t-{3-[4-(trifluoromethyl)phenyl]propyl}urea

Prepared from isoquinoline-5-carboxylic acid and

- 5 3-[4-(trifluoromethyl)phenyl]propylamine (Description 22).

m/z (ES⁺) 374 (M + H)⁺.

Example 20*N*-Isoquinolin-8-yl-*N*^t-[4-(trifluoromethyl)benzyl]urea

- 10 Prepared from isoquinoline-8-carboxylic acid and 4-(trifluoromethyl)benzylamine.

m/z (ES⁺) 346 (M + H)⁺.

Example 21*N*-[3-Fluoro-4-(trifluoromethyl)benzyl]-*N*^t-isoquinolin-5-ylurea

- 15 Prepared from isoquinoline-5-carboxylic acid and 3-fluoro-4-

(trifluoromethyl)benzylamine. *m/z* (ES⁺) 364 (M + H)⁺.

Example 22*N*-[2-Fluoro-4-(trifluoromethyl)benzyl]-*N*^t-isoquinolin-5-ylurea

- 20 Prepared from isoquinoline-5-carboxylic acid and 2-fluoro-4-

(trifluoromethyl)benzylamine. *m/z* (ES⁺) 364 (M + H)⁺.

Example 23*N*-Isoquinolin-5-yl-*N*^t-{3-[3-(trifluoromethyl)phenyl]propyl}urea

- 25 Prepared from isoquinoline-5-carboxylic acid and

3-[3-(trifluoromethyl)phenyl]propylamine (Description 23).

m/z (ES⁺) 374 (M + H)⁺.

Example 24

- 30 *N*-Isoquinolin-5-yl-*N*^t-[4-(trifluoromethoxy)benzyl]urea

Prepared from isoquinoline-5-carboxylic acid and

4-(trifluoromethoxy)benzylamine. *m/z* (ES⁺) 362 (M + H)⁺.

Example 25N-[6-(4-Fluorophenyl)pyridin-3-yl]methyl-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and [6-(4-fluorophenyl)pyridin-3-yl]methylamine (Description 25). m/z (ES⁺) 373 (M + H)⁺.

5

Example 26N-Isoquinolin-8-yl-N'-{3-[4-(trifluoromethyl)phenyl]propyl}urea

Prepared from isoquinoline-8-carboxylic acid and 3-[4-(trifluoromethyl)phenyl]propylamine (Description 22).

10 m/z (ES⁺) 374 (M + H)⁺.**Example 27**N-Quinolin-5-yl-N'-{3-[4-(trifluoromethyl)phenyl]propyl}urea

Prepared from quinoline-5-carboxylic acid and 3-[4-(trifluoromethyl)phenyl]propylamine (Description 22).
15 m/z (ES⁺) 374 (M + H)⁺.

Example 28N-Isoquinolin-8-yl-N'-{3-[3-(trifluoromethyl)phenyl]propyl}urea

20 Prepared from isoquinoline-8-carboxylic acid and 3-[3-(trifluoromethyl)phenyl]propylamine (Description 23).
 m/z (ES⁺) 374 (M + H)⁺.

Example 29

25 N-Quinolin-5-yl-N'-{3-[3-(trifluoromethyl)phenyl]propyl}urea
Prepared from quinoline-5-carboxylic acid and 3-[3-(trifluoromethyl)phenyl]propylamine (Description 23).
 m/z (ES⁺) 374 (M + H)⁺.

30

Example 30N-Isoquinolin-8-yl-N-[4-(trifluoromethoxy)benzyl]urea

Prepared from isoquinoline-8-carboxylic acid and 4-(trifluoromethoxy)benzylamine. m/z (ES⁺) 362 (M + H)⁺.

Example 31N-Quinolin-5-yl-N-[4-(trifluoromethoxy)benzyl]urea

Prepared from quinoline-5-carboxylic acid and 4-(trifluoromethoxy)benzylamine.

5 m/z (ES⁺) 362 (M + H)⁺.

Example 32N-(2,3-Dihydro-1H-inden-2-ylmethyl)-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 2,3-dihydro-1H-inden-2-

10 ylmethylamine. m/z (ES⁺) 318 (M + H)⁺.

Example 33N-Isoquinolin-5-yl-N-(4-phenylcyclohexyl)urea

Prepared from isoquinoline-5-carboxylic acid and 4-phenylcyclohexylamine.

15 m/z (ES⁺) 346 (M + H)⁺.

Example 34N-Isoquinolin-5-yl-N-(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-6-ylmethyl)urea

Prepared from isoquinoline-5-carboxylic acid and 6,7,8,9-tetrahydro-5H-

20 benzo[a][7]annulen-6-ylmethylamine hydrochloride (Description 26).

m/z (ES⁺) 346 (M + H)⁺.

Example 35N-Isoquinolin-5-yl-N-(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethyl)urea

25 Prepared from isoquinoline-5-carboxylic acid and 6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethylamine hydrochloride (Description 28).

m/z (ES⁺) 346 (M + H)⁺.

Example 36

30 N-isoquinolin-5-yl-N-{[5-(trifluoromethyl)pyridin-2-yl]methyl}urea

Prepared from isoquinoline-5-carboxylic acid and 2-aminomethyl-5-(trifluoromethyl)pyridine (Description 2). m/z (ES⁺) 347 (M + H)⁺.

Example 37N-[(4-*tert*-Butylpyridin-2-yl)methyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 2-aminomethyl-4-*tert*-butylpyridine (Description 5). *m/z* (ES⁺) 335 (M + H)⁺.

5

Example 38N-[(6-*tert*-Butylpyridin-3-yl)methyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 3-aminomethyl-6-*tert*-butylpyridine (Description 11). *m/z* (ES⁺) 335 (M + H)⁺.

10

Example 39N-[(2-*tert*-Butylpyridin-4-yl)methyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 4-aminomethyl-2-*tert*-butylpyridine (Description 13). *m/z* (ES⁺) 335 (M + H)⁺.

15

Example 40N-[(6-*tert*-Butylpyridin-2-yl)methyl]-N'-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 2-aminomethyl-6-*tert*-butylpyridine (Description 16). *m/z* (ES⁺) 335 (M + H)⁺.

20

Example 41N-Isoquinolin-5-yl-N'-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea

Prepared from isoquinoline-5-carboxylic acid and 3-aminomethyl-6-(trifluoromethyl)pyridine. *m/z* (ES⁺) 347 (M + H)⁺.

25

Example 42N-Isoquinolin-5-yl-N'-{3-[6-(trifluoromethyl)pyridin-3-yl]propyl}urea

Prepared from isoquinoline-5-carboxylic acid and 3-[6-(trifluoromethyl)pyridin-3-yl]propylamine (Description 18). *m/z* (ES⁺) 375 (M + H)⁺.

30

Example 43

N-Isoquinolin-5-yl-N-[3-(1H-pyrazol-1-yl)benzyl]urea

Prepared from isoquinoline-5-carboxylic acid and 3-(1H-pyrazol-1-yl)benzylamine hydrochloride (Description 29). m/z (ES $^+$) 344 ($M + H$) $^+$.

5

Example 44

N-Isoquinolin-5-yl-N-[4-(1H-pyrazol-1-yl)benzyl]urea

Prepared from isoquinoline-5-carboxylic acid and 4-(1H-pyrazol-1-yl)benzylamine hydrochloride (Description 30). m/z (ES $^+$) 344 ($M + H$) $^+$.

10

Example 45

N-Isoquinolin-5-yl-N-[{(2-phenyl-1,3-thiazol-5-yl)methyl]urea}

Prepared from isoquinoline-5-carboxylic acid and (2-phenyl-1,3-thiazol-5-yl)methylamine. m/z (ES $^+$) 361 ($M + H$) $^+$.

15

Example 46

N-Isoquinolin-5-yl-N-[{(2-thien-2-yl-1,3-thiazol-4-yl)methyl]urea}

Prepared from isoquinoline-5-carboxylic acid and (2-thien-2-yl-1,3-thiazol-4-yl)methylamine. m/z (ES $^+$) 367 ($M + H$) $^+$.

20

Example 47

N-Isoquinolin-5-yl-N-[{(4-phenyl-1,3-thiazol-2-yl)methyl]urea}

Prepared from isoquinoline-5-carboxylic acid and (4-phenyl-1,3-thiazol-2-yl)methylamine. m/z (ES $^+$) 361 ($M + H$) $^+$.

25

Example 48

N-Isoquinolin-5-yl-N-[{(2-phenyl-1,3-thiazol-4-yl)methyl]urea}

Prepared from isoquinoline-5-carboxylic acid and (2-phenyl-1,3-thiazol-4-yl)methylamine. m/z (ES $^+$) 361 ($M + H$) $^+$.

30

Example 49N-Isoquinolin-5-yl-N-[2-(4-phenyl-1,3-thiazol-2-yl)ethyl]urea

Prepared from isoquinoline-5-carboxylic acid and 2-(4-phenyl-1,3-thiazol-2-yl)ethylamine. m/z (ES $^+$) 375 ($M + H$) $^+$.

5

Example 50N-Isoquinolin-5-yl-N-[(5-phenylisoxazol-3-yl)methyl]urea

Prepared from isoquinoline-5-carboxylic acid and (5-phenylisoxazol-3-yl)methylamine. m/z (ES $^+$) 345 ($M + H$) $^+$.

10

Example 51N-Isoquinolin-5-yl-N-[(3-phenylisoxazol-5-yl)methyl]urea

Prepared from isoquinoline-5-carboxylic acid and (3-phenylisoxazol-5-yl)methylamine. m/z (ES $^+$) 345 ($M + H$) $^+$.

15

Example 52N-(8-Fluoroisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 8-fluoroisoquinolin-5-amine (Description 43) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. m/z (ES $^+$) 364 ($M + H$) $^+$.

20

Example 53N-Isoquinolin-5-yl-N-methyl-N-[4-(trifluoromethyl)benzyl]urea

Sodium hydride (60 % dispersion in oil, 7 mg, 0.17 mmol) was added to a suspension *N*-isoquinolin-5-yl-*N*-[4-(trifluoromethyl)benzyl]urea (Example 14; 48 mg, 0.14 mmol) in THF (3 mL) at room temperature and the reaction was stirred until effervescence ceased (20 minutes). Methyl iodide (11 μ L, 0.17 mmol) was added and the reaction stirred at room temperature for 3 hours. TLC analysis (10 % MeOH in CH₂Cl₂) indicated only one major product. The reaction was evaporated *in vacuo* and the product isolated by preparative TLC (4 % MeOH in CH₂Cl₂) to give the title compound. m/z (ES $^+$) 360 ($M + H$) $^+$.

Examples 54 to 60 were prepared according to the procedure of Description 60.

Example 54

N¹-Isoquinolin-5-yl-N-methyl-N-[4-(trifluoromethyl)benzyl]urea

Prepared from isoquinoline-5-carboxylic acid and N-methyl-N-[4-(trifluoromethyl)benzyl]amine (Description 31). *m/z* (ES⁺) 190 (M + H)⁺.

5

Example 55

N-Isoquinolin-5-yl-N-[1-[4-(trifluoromethyl)phenyl]ethyl]urea

Prepared from isoquinoline-5-carboxylic acid and 1-[4-(trifluoromethyl)phenyl]ethylamine (Description 32).

10 *m/z* (ES⁺) 360 (M + H)⁺.**Example 56**

N-(1,3-Diphenylpropyl)-N¹-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 1,3-diphenylpropylamine (Description 33). *m/z* (ES⁺) 382 (M + H)⁺.

15

Example 57

N-Isoquinolin-5-yl-N-[3-phenyl-1,2,4-oxadiazol-5-yl)methyl]urea

Prepared from isoquinoline-5-carboxylic acid and (3-phenyl-1,2,4-oxadiazol-5-yl)methylamine hydrochloride (Description 34). *m/z* (ES⁺) 346 (M + H)⁺.

20

Example 58

N-[(2-Benzyl-1,3-thiazol-4-yl)methyl]-N¹-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 2-benzyl-1,3-thiazol-4-yl)methylamine (Description 35). *m/z* (ES⁺) 375 (M + H)⁺.

25

Example 59

N-Isoquinolin-5-yl-N-[[1-(2-methylphenyl)-1H-pyrazol-4-yl]methyl]urea

Prepared from isoquinoline-5-carboxylic acid and [1-(2-methylphenyl)-1H-pyrazol-4-yl]methylamine (Description 36). *m/z* (ES⁺) 358 (M + H)⁺.

30

Example 60

N-(3-Methoxyisoquinolin-8-yl)-N¹-[4-(trifluoromethyl)benzyl]urea

Prepared from 3-methoxyisoquinoline-8-carboxylic acid (Description 56) and 4-(trifluoromethyl)benzylamine. *m/z* (ES⁺) 376 (M + H)⁺.

5

Example 61

N-Cinnolin-5-yl-N¹-[4-(trifluoromethyl)benzyl]urea

Prepared from cinnolin-5-amine (*Sci Pharm.* 1982, **50**, 246) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure 10 of Description 61. *m/z* (ES⁺) 347 (M + H)⁺.

Examples 62 to 64 were prepared according to the procedure of Description 60.

Example 62

15 N-(4-tert-Butylbenzyl)-N¹-cinnolin-5-ylurea

Prepared from cinnolin-5-amine (*Sci Pharm.* 1982, **50**, 246) and (4-*tert*-butylbenzyl)acetic acid. *m/z* (ES⁺) 335 (M + H)⁺.

Example 63

20 N-(3-Cyclohexylpropyl)-N¹-isoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and 3-cyclohexylpropylamine hydrochloride (Description 37). *m/z* (ES⁺) 312 (M + H)⁺.

Example 64

25 N-Isoquinolin-5-yl-N¹-(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-yl)urea

Prepared from isoquinolin-5-amine and 6,7,8,9-tetrahydro-5H-benzo[a][7]annulene-7-carboxylic acid (Description 38). *m/z* (ES⁺) 332 (M + H)⁺.

Example 65

30 N-Isoquinolin-5-yl-N¹-[4-(trifluoromethyl)benzyl]thiourea

To a solution of 1,1'-thiocarbonyldi-2(1*H*)-pyridone (330 mg, 1.4 mmol) in dichloromethane (13 ml) under nitrogen was added, dropwise, a solution of 4-(trifluoromethyl)benzylamine (200 µl, 1.4 mmol) in dichloromethane (10 ml).

The solution was stirred at room temperature for 16 hours. 5-Aminoisouinoline (245 mg, 0.0017 mol) was added to the reaction mixture, which was then heated at reflux for 2 days and evaporated. Preparative TLC (eluant 5% methanol/ 95% dichloromethane) gave a product band also containing 5-aminoisoquinoline. The 5 mixed product (230 mg) was dissolved in acetonitrile (40 ml) and tetrafluorophthalic anhydride (700 mg, 3.2 mmol) was added. The reaction was stirred at room temperature for 16 hours. Ethyl acetate (60 ml) was added to the reaction mix which was then washed with saturated aqueous sodium bicarbonate (3 x 20 ml). The organic extract was evaporated and the residue purified by 10 preparative TLC (eluant system 5% methanol/ 95% dichloromethane) to give the title compound (77 mg, 23%). m/z (ES⁺) 362 (M + 1)⁺.

Example 66

N-Isoquinolin-6-yl-N-[4-(trifluoromethyl)benzyl]urea

15 Prepared from 6-aminoisoquinoline (Description 51) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. m/z (ES⁺) 346 (M + H)⁺.

Example 67

N-Isoquinolin-6-yl-N-[4-(trifluoromethoxy)benzyl]urea

Prepared from 6-aminoisoquinoline (Description 51) and [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to the procedure of Description 61. m/z (ES⁺) 362 (M + H)⁺.

25

Example 68

N-(3-Methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 3-methylisoquinolin-5-amine (Description 45) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. m/z (ES⁺) 360 (M + H)⁺.

30

Example 69

N-(1-Chloroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea

Prepared from 1-chloroisoquinolin-5-amine (Description 48) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. *m/z* (ES⁺) 380, 382 (M + H)⁺.

Example 70

N-[1-(Dimethylamino)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

10 *N*-(1-Chloroisoquinolin-5-yl)-*N'*-(4-trifluoromethylbenzyl)urea (Example 69; 60 mg) was suspended in ethanol (5 ml). Ethanolic dimethylamine (33%, 2 ml) was added and the mixture heated to 100 °C in a sealed tube for 16 hours after which time TLC indicated complete reaction. The reaction mixture was evaporated and the residue purified by preparative thin layer chromatography (5% methanol-dichloromethane eluant) to give the title compound (20 mg).

15 *m/z* (ES⁺) 389 (M + H)⁺.

Example 71

N-(3-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea

20 Prepared from 3-methylisoquinolin-5-amine (Description 45) and [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to the procedure of Description 61. *m/z* (ES⁺) 376 (M + H)⁺.

Example 72

N-(3-Methylisoquinolin-8-yl)-N'-[4-(trifluoromethyl)benzyl]urea

25 A sample of 3-methyl-5-nitroisoquinoline (Description 44) enriched in the nitration byproduct 3-methyl-8-nitroisoquinoline was reduced according to Description 45 and the mixture of amines reacted with [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. Isomer separation of the products gave the title compound.

30 *m/z* (ES⁺) 360 (M + H)⁺.

Example 73N-(3-Chloroisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 3-chloroisoquinolin-5-amine (Description 50) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. *m/z* (ES⁺) 380, 382 (M + H)⁺.

5

Example 74N-(3-Methylcinnolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 3-methylcinnolin-5-amine and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of Description 61. *m/z* (ES⁺) 361 (M + H)⁺.

10

Example 75N-Cinnolin-5-yl-N-[4-(trifluoromethoxy)benzyl]urea

15 Prepared from cinnolin-5-amine [*Sci Pharm.* 1982, **50**, 246] and [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to the procedure of Description 61. *m/z* (ES⁺) 363 (M + H)⁺.

Example 76

20 N-(1-hydroxyisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

N-(1-chloroisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea (Example 69; 47 mg, 0.12 mmol) was added to a mixture of 3N HCl (aq. 5 ml) and THF (1 ml). The mixture was heated at 90 °C for 20 hours, then 5N HCl (aq. 2 ml) was added and the reaction heated at 90 °C for a further 20 hours. After cooling to room temperature, ethyl acetate (20 ml) was added and the layers separated (some solid was suspended in the organic layer). The organic phase was washed with saturated aqueous NaHCO₃ (20 ml), then evaporated. The residue was triturated in refluxing isopropyl alcohol (5 ml), then cooled to room temperature. The white solid was collected by filtration and washed with isopropyl alcohol (2 x 1 ml) to give the title compound (22 mg). *m/z* (ES⁺) 362 (M + H)⁺.

25

30

Example 77N-[4-(trifluoromethyl)benzyl]-N-[3-(trifluoromethyl)isoquinolin-5-yl]urea

Prepared from 3-(trifluoromethyl)isoquinolin-5-amine (Description 64) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure
5 of Description 61. m/z (ES⁺) 414 (M + H)⁺.

Example 78N-(1-chloro-3-ethylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 1-chloro-3-ethylisoquinolin-5-amine (Description 66) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure
10 of Description 61. m/z (ES⁺) 408 , 410 (M + H)⁺.

The following quinolin-6-yl derivatives were also prepared by similar methodology:

15

Example 79N-phenyl-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and phenyl isocyanate. m/z (ES⁺) 264 (M + H)⁺.

20

Example 80N-(2-naphthyl)-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 2-naphthyl isocyanate.
 m/z (ES⁺) 314 (M + H)⁺.

25

Example 81N-(4-nitrophenyl)-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 4-nitrophenyl isocyanate.
 m/z (ES⁺) 309 (M + H)⁺.

30

Example 82N-[3,5-bis(trifluoromethyl)phenyl]-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 3,5-bis(trifluoromethyl)phenyl isocyanate.
 m/z (ES⁺) 400 (M + H)⁺.

Example 83N-(4-phenoxyphenyl)-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 4-phenoxyphenyl isocyanate.

5 m/z (ES⁺) 356 (M + H)⁺.

Example 84N-(4-acetylphenyl)-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 4-acetylphenyl isocyanate.

10 m/z (ES⁺) 306 (M + H)⁺.

Example 85N-benzyl-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and benzyl isocyanate. m/z (ES⁺) 278 (M + H)⁺.

15

Example 86N-[quinolin-6-yl]-N'-[4-(trifluoromethoxy)phenyl]urea

Prepared from 6-aminoquinoline and 4-(trifluoromethoxy)phenyl isocyanate.

m/z (ES⁺) 348 (M + H)⁺.

20

Example 87N-(4-cyanophenyl)-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 4-cyanophenyl isocyanate.

m/z (ES⁺) 289 (M + H)⁺.

25

Example 88N-(1,1'-biphenyl-4-yl)-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 4-biphenyl isocyanate.

m/z (ES⁺) 340 (M + H)⁺.

30

Example 89N-[4-(dimethylamino)phenyl]-N'-[quinolin-6-yl]urea

Prepared from 6-aminoquinoline and 4-(dimethylamino)phenyl isocyanate.

m/z (ES⁺) 307 (M + H)⁺.

Example 90

N-(1,3-benzodioxol-5-yl)-N'-[quinolin-6-yl]urea

5 Prepared from 6-aminoquinoline and 3,4-(methylenedioxy)phenyl isocyanate.

m/z (ES⁺) 308 (M + H)⁺.

Example 91

N-cyclohexyl-N'-[quinolin-6-yl]urea

10 Prepared from 6-aminoquinoline and cyclohexyl isocyanate.

m/z (ES⁺) 270 (M + H)⁺.

Example 92

N-[(+/-)-1-phenylethyll]-N'-[quinolin-6-yl]urea

15 Prepared from 6-aminoquinoline and (+/-)-1-phenylethyl isocyanate.

m/z (ES⁺) 292 (M + H)⁺.

The above exemplified compounds of the present invention have been tested in
the following assay and generally possess an IC₅₀ < 1 μM and, in the majority of
20 cases, < 200 nM.

Biological Methodology

Determination of *in vitro* activity

CHO cells, stably expressing recombinant human VR1 receptors and plated into
25 black-sided 384-well plates, were washed twice with assay buffer (Hepes-buffered
saline) and then incubated with 1uM Fluo-3-AM for 60 minutes in darkness.
Cells were washed twice more to remove excess dye, before being placed, along
with plates containing capsaicin and test compounds in a Molecular Devices
FLIPR. The FLIPR simultaneously performed automated pharmacological
30 additions and recorded fluorescence emmission from Fluo-3. In all experiments,
basal fluorescence was recorded, before addition of test compounds and
subsequent addition of a previously determined concentration of capsaicin that
evoked 80% of the maximum respnse. Inhibition of capsaicin evoked increases
in intracellular [Ca²⁺] were expressed relative to wells on the same plate to which

capsaicin was added in the absence of test compounds. Increases in intracellular [Ca²⁺] occurring after addition of test compound alone, prior to addition of capsaicin, allow determination of intrinsic agonist or partial agonist activity, if present.

5

Determination of *in vivo* efficacy in a capsaicin paw flinch model

(Method adapted from Taniguchi *et al*, 1997, *Br J Pharmacol.* 122(5):809-12)

To determine *in vivo* functional occupancy of VR1 receptors, compounds are administered orally to male Sprague Dawley rats typically 1 hour prior to

10 receiving an intraplantar injection of capsaicin (2µg dissolved in ethanol) and the number of flinches of the injected paw is recorded for 5 minutes immediately thereafter. Statistical analysis is performed using one-way ANOVA followed by Dunnett's test; p values <0.05 compared to capsaicin/vehicle-treated rats are considered significant.

15

Determination of *in vivo* efficacy in a model of inflammatory pain

(Method adapted from Hargreaves *et al*, 1988 *Pain*, 32(1):77-88).

Antinociceptive activity is determined using a rat carrageenan-induced thermal hyperalgesia assay. Inflammatory hyperalgesia is induced by intraplantar

20 injection of carrageenan (lambda-carrageenan 0.1 ml of 1% solution made up in saline) into one hind paw. Compounds are given orally typically 2 hours after carrageenan and paw withdrawal latencies determined 1 hour later. Paw withdrawal latencies to application of noxious thermal stimuli to plantar surface of the hind paw are measured using the Hargreaves apparatus. Thermal 25 hyperalgesia is defined as the difference in paw withdrawal latencies for saline/vehicle- and carrageenan/vehicle-treated rats. Paw withdrawal latencies for drug treated rats are expressed as a percentage of this response. Statistical analysis is performed using one-way ANOVA followed by Dunnett's test; p values <0.05 compared to carrageenan/vehicle-treated rats are considered significant.

30

Example 93N-(1-Methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 1-methylisoquinolin-5-amine (Description 68) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure
5 of Description 61. m/z (ES⁺) 360 (M + H)⁺.

Example 94N-(1-Methylisoquinolin-5-yl)-N-[4-(trifluoromethoxy)benzyl]urea

Prepared from 1-methylisoquinolin-5-amine (Description 68) and
10 [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to the
procedure of Description 61. m/z (ES⁺) 376 (M + H)⁺.

Example 95N-(6,8-Difluoro-3-methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

15 Prepared from 6,8-difluoro-3-methylisoquinolin-5-amine (Description 73) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.
 m/z (ES⁺) 396 (M + H)⁺.

Example 96

20 N-[3-Methyl-7-(trifluoromethyl)isoquinolin-5-yl]-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 3-methyl-7-(trifluoromethyl)isoquinolin-5-amine (Description 74) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to
Description 61. m/z (ES⁺) 428 (M + H)⁺.

25

Example 97N-(8-Fluoro-3-methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 8-fluoro-3-methylisoquinolin-5-amine (Description 76) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.
30 m/z (ES⁺) 378 (M + H)⁺.

Example 98N-(6-Fluoro-3-methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 6-fluoro-3-methylisoquinolin-5-amine (Description 79) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.
5 m/z (ES⁺) 378 (M + H)⁺.

Example 99N-(6-Fluoro-3-methylisoquinolin-5-yl)-N-[4-(trifluoromethoxy)benzyl]urea

10 Prepared from 6-fluoro-3-methylisoquinolin-5-amine (Description 79) and [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to Description 61.
 m/z (ES⁺) 394 (M + H)⁺.

Example 100

15 N-(3-Methylcinnolin-5-yl)-N-[4-(trifluoromethoxy)benzyl]urea

Prepared from 3-methylcinnolin-5-amine and
[4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to the
procedure of Description 61. m/z (ES⁺) 377 (M + H)⁺.

20

Example 101N-(7-Methoxyisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 7-methoxyisoquinolin-5-amine (Description 82) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.
 m/z (ES⁺) 376 (M + H)⁺.

25

Example 102N-(1,3-Dimethylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 1,3-dimethylisoquinolin-5-amine (Description 83) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.
30 m/z (ES⁺) 374 (M + H)⁺.

Example 103N-(7-Chloro-3-methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 7-chloro-3-methylisoquinolin-5-amine (Description 86) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.

5 m/z (ES⁺) 394 (M + H)⁺.

Example 104N-(7-Chloroisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 7-chloroisoquinolin-5-amine (Description 87) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.

10 m/z (ES⁺) 380 (M + H)⁺.

Example 105N-(8-Fluoro-3-methoxyisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

15 Prepared from 8-fluoro-3-methoxyisoquinoline-5-carboxylic acid (Description 88) and 4-(trifluoromethyl)benzylamine according to Description 60. m/z (ES⁺) 394 (M + H)⁺.

Example 106

20 N-(6-Fluoroisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 6-fluoroisoquinolin-5-amine (Description 89) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61. m/z (ES⁺) 364 (M + H)⁺.

25

Example 107N-(6-Fluoroisoquinolin-5-yl)-N-[4-(trifluoromethoxy)benzyl]urea

Prepared from 6-fluoroisoquinolin-5-amine (Description 89) and [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to Description 61. m/z (ES⁺) 394 (M + H)⁺.

30

Example 108N-(7-Fluoroisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 7-fluoroisoquinolin-5-amine (Description 90) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.

35 m/z (ES⁺) 364 (M + H)⁺.

Example 109N-(4-Methylisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 4-methylisoquinolin-5-amine (Description 91) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61.

5 m/z (ES⁺) 360 (M + H)⁺.

Example 110N-[8-(trifluoromethyl)isoquinolin-5-yl]-N-[4-(trifluoromethyl)benzyl]urea

To a solution of 8-(trifluoromethyl)isoquinolin-5-amine (Description 93; 150 mg, 10 0.708 mmol) in CDCl₃ (10 ml) was added [4-(trifluoromethyl)benzyl]isocyanate (Description 58) [0.506M soln in DCM; 1.403 ml, 0.71 mmol] and the resulting mixture heated at reflux overnight. NMR analysis showed a deficit of the [4-(trifluoromethyl)benzyl]isocyanate in comparison to remaining 8-(trifluoromethyl)isoquinolin-5-amine so a further portion of [4-(trifluoromethyl)benzyl]isocyanate [0.506M solution in DCM] (1.403ml ; 15 0.71mmol) was added and refluxing continued for 2 days. The cooled reaction mixture was evaporated to dryness and purified by column chromatography on silica elution with 1% MeOH in DCM + 0.5% NH₄OH. NMR showed the product was the bis acylated urea. This material was dissolved in methanol (5 ml) and 20 K₂CO₃ (500 mg, 3.6 mmol) added and the mixture stirred at room temperature for 2.5 hours. The mixture was filtered and the residue purified by preparative TLC eluting with 10% MeOH in DCM + 0.5% NH₄OH to give the title compound (100 mg, 34%) as a white solid. m/z (ES⁺) 414 (M + H)⁺.

25

Example 111N-[6-(trifluoromethyl)isoquinolin-5-yl]-N-[4-(trifluoromethyl)benzyl]urea

To a solution of 6-(trifluoromethyl)isoquinolin-5-amine (Description 98; 100 mg, 0.47 mmol) in anhydrous toluene (5 ml) was added [4-(trifluoromethyl)benzyl]isocyanate (Description 58) [0.506M soln in DCM] (1.88 ml ; 0.94 mmol) and the mixture heated at reflux overnight. Further [4-(trifluoromethyl)benzyl]isocyanate [0.506M soln in DCM] (1.88 ml ; 0.94 mmol) was added and heating continued for 4 days. The toluene was removed, the residue dissolved in methanol (10 ml) and a spatula end of potassium carbonate added. The mixture was then heated at reflux for 15 mins. The mixture was

cooled and filtered and the filtrate evaporated. The residue was purified by mass directed HPLC to give the title compound (8 mg, 4%) as a white solid. m/z (ES⁺) 414 ($M + H$)⁺.

5

Example 112

N-[7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

Prepared from 7-(trifluoromethyl)isoquinolin-5-amine (Description 99) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61. m/z (ES⁺) 414 ($M + H$)⁺.

10

Example 113

N-[7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethoxy)benzyl]urea

Prepared from 7-(trifluoromethyl)isoquinolin-5-amine (Description 99) and [4-(trifluoromethoxy)benzyl]isocyanate (Description 59) according to Description 61. m/z (ES⁺) 414 ($M + H$)⁺.

15

Example 114

N-(6-Fluoro-1-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea

Prepared from 6-fluoro-1-methylisoquinolin-5-amine (Description 103) and [4-(trifluoromethyl)benzyl]isocyanate (description 58) according to the procedure of description 61. m/z (ES⁺) 378 ($M + H$)⁺.

Example 115

N-(1-Cyanoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea

To a solution of N-(1-chloroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea (Example 69) (250 mg, 0.7mmol) in DMF (5 ml) was added zinc cyanide (43 mg, 0.37 mmol) and tetrakis(triphenylphosphine)palladium (76 mg, 0.07mmol). The reaction was heated at 80°C, under an atmosphere of nitrogen, for 72 hr, with the addition of extra tetrakis(triphenylphosphine)palladium (76 mg, 0.07 mmol) after 16 hr. Reaction mixture was quenched with water and extracted with ethyl acetate (3 x 5 ml), dried over MgSO₄ and evaporated. The residue was purified by flash column chromatography using an eluant system of 3% methanol/97% DCM increasing to 5% MeOH/ 95% DCM. Recrystallisation in ethanol of a small portion of product gave a pure sample of the title compound (50 mg, 65.6%). m/z (ES⁺) 371, 373 ($M + H$)⁺.

Example 116

N-[1-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

Prepared from methyl 5-aminoisoquinoline-1-carboxylate (Description 106) and

- 5 [4-(trifluoromethyl)benzyl]isocyanate (description 58) according to the procedure
of description 61. m/z (ES $^+$) 404 ($M + H$) $^+$.

Example 117

N-(1-Carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea

- 10 N-[1-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea
(Example 116, 55 mg, 0.136 mmol) was dissolved in a mixture of THF (3 ml),
methanol (1 ml) and water (1 ml), then lithium hydroxide monohydrate (6 mg,
0.14 mmol) was added. The reaction was stirred at room temperature until all the
ester had been consumed, then the solvents were evaporated and 5% aqueous
15 NaH₂PO₄ solution (pH 4, 5 ml) was added to the residue. After stirring for 15
min. the pale yellow solid was collected by filtration, washed with water (2 ml)
and dried under vacuum to give the title compound (39 mg, 73 %). m/z (ES $^+$) 390
($M + H$) $^+$.

20

Example 118

N-(1-Aminoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea

- A mixture of N-(1-carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea
(Example 117, 309 mg, 0.794 mmol), diphenylphosphoryl azide (210 μ l, 0.975 mmol)
and triethylamine (210 μ l, 1.50 mmol) in 1,4-dioxane (25 ml) was heated at 100 °C,
25 under a nitrogen atmosphere for 1.5 h. Water (0.25 ml) was then added and the
reaction mixture heated for a further 1 hour. The reaction mixture was then cooled to
room temperature, filtered and the filtrate evaporated. The residue was purified
using a Bond-Elut SCX ion-exchange cartridge, first eluting non-basic materials with
methanol, then eluting the product with 2M methanolic ammonia. The basic fractions
30 were evaporated and further purified by flash column chromatography (eluant 5%
MeOH – 95% dichloromethane increasing to 10% MeOH – 90% dichloromethane).
The product was then passed through a second SCX purification to give the title
compound (77 mg, 27%). m/z (ES $^+$) 361 ($M + H$) $^+$.

Example 119

N-[1-(Hydroxymethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

N-[1-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

(Example 116, 70 mg, 0.174 mmol) was suspended in a mixture of THF (5 ml) and
5 toluene (5 ml). Lithium borohydride (50 mg, 2.27 mmol) was added and the
reaction mixture heated at 60 °C for 1 hour. The reaction was cooled to room
temperature and allowed to stand for 1 week. The crystalline product was
collected by filtration, washed with toluene (2 ml), then triturated with 1:1 THF-
dichloromethane (2 ml), triturated again with THF (2 ml) and dried under
10 vacuum to give the title compound (8 mg, 12 %). *m/z* (ES⁺) 376 (M + H)⁺.

Example 120

N-[3-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

Prepared from methyl 5-aminoisoquinoline-3-carboxylate (Description 107) and
15 [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description
61. *m/z* (ES⁺) 404 (M + H)⁺.

Example 121

N-(3-Carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea

20 Prepared from N-[3-(methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea (Example 120) according to the procedure of
Example 117. *m/z* (ES⁺) 390 (M + H)⁺.

Example 122

25 N-[3-(Dimethylamino)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

Prepared from 3-(dimethylamino)isoquinolin-5-amine (Description 109) and [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to the procedure of
description 61. *m/z* (ES⁺) 389 (M + H)⁺.

30

Example 123

N-[3-(2-Aminoethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea

To a solution of *tert*-butyl 2-(5-aminoisoquinolin-3-yl)ethylcarbamate (Description
116; 200 mg, 0.7 mmol) in deuterated chloroform (5 ml) was added [4-(trifluoromethyl)benzyl]isocyanate (0.506M solution in DCM) (Description 58;

1.38 ml, 0.7 mmol), and the resulting mixture heated at reflux overnight. The reaction mixture was cooled and the precipitate removed by filtration, washed with DCM and dried. The solid was dissolved in methanol (10 ml) and hydrogen chloride gas passed through the mixture for 5 mins, after which time the mixture 5 was left standing for 1 hour. The mixture was evaporated and purified using an SCX cartridge - appropriate fractions were evaporated to give the title compound (25 mg, 9%) as a white solid. *m/z* (ES⁺) 389 (M + H)⁺.

Example 124

10 N-(8-Methoxyisoquinolin-5-yl)-N-[4-(trifluoromethyl)benzyl]urea

Prepared from 8-methoxyisoquinolin-5-amine which was prepared from 8-methoxy-5-nitroisoquinoline (*J. Het. Chem.* 37(5), 1293) according to Description 43 and immediately used in reaction with [4-(trifluoromethyl)benzyl]isocyanate (Description 58) according to Description 61. *m/z* (ES⁺) 376 (M + H)⁺.

15

Example 125

N-Isoquinolin-7-yl-N-[4-(trifluoromethyl)benzyl]urea

A mixture of isoquinolin-7-yl trifluoromethanesulfonate (Description 117, 1.04 g, 3.75 mmol), cesium carbonate (1.6 g, 4.88 mmol), benzophenone imine (747 mg, 20 4.13 mmol), BINAP (100 mg, 0.16 mmol) and palladium acetate (18 mg, 0.08 mmol) in tetrahydrofuran (15 ml) was degassed (N₂ x 3) then heated at reflux for 18 h. More BINAP (100 mg, 0.16 mmol) and palladium acetate (18 mg, 0.08 mmol) were added and the reaction heated for a further 24 h. The reaction was then cooled to room temperature and partitioned between ethyl acetate (100 ml) 25 and water (100 ml). The aqueous layer was extracted with more ethyl acetate (50 ml) and the combined organic layers were evaporated. The residue was taken up in tetrahydrofuran (40 ml) and 2N hydrochloric acid (aq. 10 ml) was added. After 2h, the THF was evaporated, 3N hydrochloric acid (aq. 100 ml) was added and the mixture washed with ethyl acetate (2 x 75 ml). The aqueous layer was then 30 basified by addition of 47% aqueous sodium hydroxide solution and extracted with dichloromethane (3 x 50 ml). The combined organic layers were dried (Na₂SO₄) and evaporated to give crude isoquinolin-7-amine (198 mg) which was reacted directly with [4-(trifluoromethyl)benzyl]isocyanate (Description 58)

according to Description 61 to give the title compound (100 mg, 8%). m/z (ES⁺) 346 ($M + H$)⁺.

Example 126

5 N - N' -Diisoquinolin-5-ylurea

Prepared from isoquinoline-5-carboxylic acid and isoquinolin-5-amine according to Description 60. m/z (ES⁺) 315 ($M + H$)⁺.

Example 127

10 N -Isoquinolin-5-yl- N -[4-(trifluoromethyl)phenyl]urea

Prepared from isoquinolin-5-amine and 4-(trifluoromethyl)phenyl isocyanate according to Description 61. m/z (ES⁺) 332 ($M + H$)⁺.

Example 128

15 N -Isoquinolin-5-yl- N -{[2-(trifluoromethyl)pyrimidin-5-yl]methyl}urea

Prepared from isoquinoline-5-carboxylic acid and 5-(aminomethyl)-2-(trifluoromethyl)pyrimidine (Description 121) according to the procedure of Description 60. m/z (ES⁺) 348 ($M + H$)⁺.

20

Example 129

Ethyl 3-{{(isoquinolin-5-ylamino)carbonyl}amino}-2-[4-(trifluoromethyl)benzyl]propanoate

Ethyl 2-cyano-3-[4-(trifluoromethyl)phenyl]prop-2-enoate (135 mg, 0.5 mmol), palladium hydroxide (20 wt% Pd (dry basis on carbon), 20 mg) in ethanol (20 ml) containing 2N hydrochloric acid (1 ml) was placed on a Parr apparatus at 35 psi hydrogen pressure and shaken for 1.5 hours. The reaction mixture was filtered and evaporated to give the corresponding amine which was taken up in THF (5 ml). In a separate flask isoquinolin-5-amine (72mg, 0.5mmol) in THF (5 ml) at 0 °C was treated with triphosgene (48 mg, 0.166 mmol) followed by triethylamine (140 μ L). After 30 minutes, the amine solution was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then filtered and evaporated. Purification by column chromatography using 2.5%methanol in dichloromethane gave the desired product (49mg). m/z (ES⁺) 446 ($M + H$)⁺.

Example 130

3-{{(isoquinolin-5-ylamino)carbonyl}amino}-2-[4-(trifluoromethyl)benzyl]propanoic acid

- 5 Ethyl 3-{{(isoquinolin-5-ylamino)carbonyl}amino}-2-[4-(trifluoromethyl)benzyl] propanoate (Example 129, 23 mg, 0.05 mmol) in aqueous THF (1:1, 2 ml) was treated with lithium hydroxide (5 mg, 0.1 mmol) and stirred at room temperature for 20 h. The mixture was evaporated then partitioned between 7 % aqueous citric acid and dichloromethane (2:1, 6ml). A precipitate formed which was 10 collected by filtration and dried azeotropically by adding toluene and evaporating to give the desired compound (8.4 mg). m/z (ES $^+$) 418 ($M + H$) $^+$.

Example 131

N-Isoquinolin-5-yl-N-[4-(morpholin-4-ylmethyl)benzyl]urea

- 15 A solution of isoquinoline-5-carbonyl azide (Description 126, 50 mg, 0.25 mmol) in toluene (5 mL) was heated at 75 °C for 1 h. The reaction was cooled to 50 °C and 4-(morpholin-4-ylmethyl)benzylamine (Description 123, 0.31 mmol) was added as a solution in CH₂Cl₂ (1 ml). The precipitated product was collected by filtration and washed with hexane, then further purified using mass-directed HPLC to give 20 the title compound (2.5 mg, 3%). m/z (ES $^+$) 376 ($M + H$) $^+$.


Example 132

N-Isoquinolin-5-yl-N-[2-(2-morpholin-4-ylethoxy)-4-(trifluoromethyl)benzyl]urea

- A solution of isoquinoline-5-carbonyl azide (Description 126, 43 mg, 0.22 mmol) in 25 toluene (4 mL) was heated at 80 °C for 50 min. The reaction was cooled to 50 °C and 2-(2-morpholin-4-ylethoxy)-4-(trifluoromethyl)benzylamine (Description 125, 66 mg, 0.22 mmol) was added as a solution in toluene (1 ml). The precipitated product was collected by filtration and washed with dichloromethane to give the title compound (83 mg, 80%). m/z (ES $^+$) 475 ($M + H$) $^+$.

CLAIMS

1. A compound of formula (I):



5

(I)

wherein

- A, B, D and E are each C or N with the proviso that one or more are N;
- R¹ and R² are each independently hydrogen, halogen, hydroxy, C₁-alkyl, C₂-alkenyl, C₂-alkynyl, haloC₁-alkyl, hydroxyC₁-alkyl, C₁-alkoxy, 10 haloC₁-alkoxy, hydroxyC₁-alkoxy, C₃-cycloalkyl, C₃-cycloalkylC₁-alkyl, NR⁷R⁸, carboxy, esterified carboxy, C₁-alkyl substituted with a group selected from NR⁷R⁸, carboxy and esterified carboxy, or C₁-alkoxy substituted with a group selected from NR⁷R⁸, carboxy and esterified carboxy;
- R³ and R⁴ are each independently hydrogen, C₁-alkyl, C₂-alkenyl or C₂-alkynyl;
- 15 R⁵ and R⁶ are, at each occurrence, independently hydrogen, C₁-alkyl, C₂-alkenyl, C₂-alkynyl, C₁-alkoxy, C₁-acyloxy, carboxy, esterified carboxy, CONR⁷R⁸, SO₂R⁷, SO₂NR⁷R⁸, aryl, heteroaryl, heterocyclyl, or C₁-alkyl substituted with a group selected from hydroxy, C₁-alkoxy, C₁-acyloxy, carboxy, esterified carboxy, NR⁷R⁸, CONR⁷R⁸, SR⁷, SO₂R⁷, SO₂NR⁷R⁸, aryl, heteroaryl and heterocyclyl;
- 20 or R⁵ and R⁶ and the carbon atom to which they are attached together form a carbocyclic ring of 3 to 6 carbon atoms;
- R⁷ and R⁸ are, at each occurrence, independently hydrogen, C₁-alkyl, C₂-alkenyl, C₂-alkynyl, C₃-cycloalkyl or fluoroC₁-alkyl;
- 25 or R⁷ and R⁸ and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C₁-alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, a group S(O) or S(O)₂, or a second nitrogen atom which will be part of a NH or NR^a moiety where R^a is C₁-alkyl optionally substituted by hydroxy or C₁-alkoxy;

X is an oxygen or sulfur atom or the group =NCN;
Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; and
n is either zero or an integer from 1 to 3;
or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.

5

2. A compound according to claim 1 in which X is O.
3. A compound according to claim 1 or 2 in which R³ and R⁴ are hydrogen.
- 10 4. A compound according to claim 1, 2 or 3 in which B is nitrogen and A, D and E are carbon.
- 15 5. A compound according to any preceding claim in which Y is an aryl group selected from unsubstituted phenyl or naphthyl and phenyl or naphthyl substituted by one or two substituents selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, phenyl, cyano, nitro, pyrazolyl, di(C₁₋₆alkyl)amino, phenoxy, -OCH₂O- and C₁₋₆alkylcarbonyl; or a heteroaryl group selected from pyridyl, thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl wherein each heteroaryl group is optionally substituted with one or two substituents selected from C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, unsubstituted heteroaryl or phenyl which may be substituted by C₁₋₆alkyl or halogen; or a carbocyclyl group which is a C₅₋₇cycloalkyl radical that is unsubstituted or substituted by a phenyl ring; or a fused-carbocyclyl group which is a C₅₋₇cycloalkyl radical that is fused to a phenyl ring.
- 20 6. A compound according to any preceding claim wherein R⁵ and R⁶ each independently represent a hydrogen atom or a C₁₋₄alkyl or phenyl group.
- 25 7. A pharmaceutical composition comprising a compound according to any preceding claim or a pharmaceutically acceptable salt or N-oxide thereof.
- 30 8. A compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or N-oxide thereof for use in a method of treatment of the human or animal body by therapy.

9. Use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or N-oxide thereof for use in the manufacture of a medicament for treating diseases and conditions in which pain and/or inflammation predominates.
10. A method of treating a subject suffering from a disease or condition in which pain and/or inflammation predominates which comprises administering to that subject a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/01302

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D215/38	C07D215/40	C07D217/22	C07D217/24	C07D217/26
	C07D237/28	C07D401/12	C07D401/14	C07D521/00	A61K31/4709
	A61K31/472	A61K31/4725	A61K31/502	A61K31/506	A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CHEMCATS 'Online! chemical abstracts service, columbus, ohio, us; XP002244788 order number T0507-0244 & "Enamine Product Listing" 15 November 2001 (2001-11-15), ENAMINE , KIEV 042, 01042, UKRAINE	1,3-6
X,P	DATABASE CHEMCATS 'Online! chemical abstracts service, columbus, ohio, us; XP002244789 order number M-161217 & "Scientific Exchange Product List" 1 January 2003 (2003-01-01), SCIENTIFIC EXCHANGE, INC. , CENTER OSSIPPEE, NH, 03814, USA	1,3-6

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

18 June 2003

07/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hanisch, I

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/01302

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AGARWAL S K ET AL: "Antiparasitic agents: Part XV - Synthesis of 2-substituted 1(3)H-imidazo'4,5-f!isoquinolines as anthelmintic agents" INDIAN JOURNAL OF CHEMISTRY, JODHPUR, IN, vol. 31B, March 1992 (1992-03), pages 177-182, XP009012271 Scheme 1, compounds 7 and 8 page 179, column 2 ---	1,3-6
X	US 5 508 288 A (FORBES IAN T ET AL) 16 April 1996 (1996-04-16) claims 1,7; example 15 ---	1-4,6-8
X	US 4 045 439 A (PRESTON JOHN ET AL) 30 August 1977 (1977-08-30) examples 17,24 ---	1-3,6
X	HONMA TERUKI ET AL: "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 2001, pages 4615-4627, XP002220243 ISSN: 0022-2623 page 4624, column 1, line 15 - line 23; figure 3; examples 4,14B; table 2 ---	1-3,5,6
X	DE 11 57 626 B (FARBWERKE HOECHST AG) 21 November 1963 (1963-11-21) examples 1-10 ---	1,3,5,6
X	DE 583 207 C (I G FARBNENINDUSTRIE AKT GES) 30 August 1933 (1933-08-30) examples 1,2,5-7,9 ---	1-4,6,8
X	WO 93 24458 A (PFIZER ;HAMANAKA ERNEST S (US)) 9 December 1993 (1993-12-09) cited in the application claims 1-5,7,9; examples 77,79,82,87 ---	1-3,5-8
X	PORADOWSKA H ET AL: "Phenylquinoline derivatives of urea " ROCZNIKI CHEMII ANNALES SOCIETATIS CHIMICAE POLONORUM, XX, XX, vol. 49, 1975, pages 1577-1580, XP009012273 ISSN: 0035-7677 examples 2-8; table 1 ---	1-3,5,6
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/01302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PORADOWSKA H ET AL: "Phenylquinoline derivatives of thiourea" POLISH JOURNAL OF CHEMISTRY, POLISH CHEMICAL SOCIETY, XX, vol. 53, 1979, pages 1895-1900, XP009012274 examples 2-8; table 1 ---	1,3,5,6
X	MUSSER J H ET AL: "Synthesis and Antilipolytic Activities of Quinolyl Carbanilates and Related Analogues" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 30, no. 1, 1987, pages 62-67, XP002244786 ISSN: 0022-2623 page 66, column 1; figure 1; example 13; table 1 ---	1
X	JOSHI K C ET AL: "Chemical Constituents of Clerodendron infortunatum Linn. and Ficus racemosa Linn." JOURNAL OF THE INDIAN CHEMICAL SOCIETY, THE INDIAN CHEMICAL SOCIETY, CALCUTTA, IN, vol. 54, 1977, pages 1104-1105, XP009012272 ISSN: 0019-4522 examples 1-50 ---	1,3,5,6
X	WO 94 14801 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 7 July 1994 (1994-07-07) claims 1-4,7,8; examples 8,11,12 ---	1,3,5-8
X	WO 00 26203 A (ISACCHI ANTONELLA ;TRAQUANDI GABRIELLA (IT); VILLA MANUELA (IT); V) 11 May 2000 (2000-05-11) claims 1,6,13,16; example 189 ---	1-3,5-8
X	DE 25 02 588 A (TROPONWERKE DINKLAGE & CO) 29 July 1976 (1976-07-29) page 25; claims 1,3; examples 39-42 ---	1-3,5-10
Y	WO 02 08221 A (BAKTHAVATCHALAM RAJAGOPAL ;DESIMONE ROBERT W (US); NEUROGEN CORP () 31 January 2002 (2002-01-31) cited in the application page 4, line 12 - line 18; claims 1,187,188,194-196 ---	1-10
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/01302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SONDHI S M ET AL: "SYNTHESIS AND ANTICANCER, ANTIINFLAMMATORY, AND ANALGESIC ACTIVITY EVALUATION OF SOME SULFA DRUG AND ACRIDINE DERIVATIVES" MONATSHEFTE FUR CHEMIE, SPRINGER VERLAG. WIEN, AT, vol. 131, no. 5, 2000, pages 511-520, XP001088543 ISSN: 0026-9247 page 517, paragraph 4 -page 518, paragraph 3; example 7</p> <p>---</p>	1-10
Y	<p>LEE ET AL: "N-(3-Acyloxy-2-Benzylpropyl)-N'-Dihydroxy tetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands" BIOORGANIC & MEDICINAL CHEMISTRY, OXFORD, GB, vol. 9, 2001, pages 1713-1720, XP002244787 ISSN: 0960-894X cited in the application page 1714, column 1, paragraph 3 -column 2, paragraph 2 page 1717, column 1, paragraph 3 -column 2, paragraph 1; figure 2; examples 18,27,28</p> <p>---</p>	1-10
P,Y	<p>WO 03 014064 A (BAYER AG ;FREITAG JOACHIM (DE); MEIER HEINRICH (DE); LOWINGER TIMO) 20 February 2003 (2003-02-20) page 10, line 11 - line 19; claims 1,14,16,17; tables 1,3-6,8</p> <p>----</p>	1-10

International application No.
PCT/GB 03/01302

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: 1-3(part), 5-10(part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 10 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1-3(part),5-10(part)

Present claims 1-3, 5-10 (in part) relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds in which the fused "A=B-D=E"-heterocycle of formula (I) is either quinoline, isoquinoline or cinnoline, thereby including all of the given examples.

It is noted that claim 1 of the application refers to prodrugs. "Prodrugs" is a functional definition which attempts to define a chemical compound in terms of a result to be achieved. This is not allowable (Article 6 PCT). "Prodrugs" is a functional definition without a specific technical guidance for the selection of the suitable derivatives in the description and without proven general knowledge to show which derivatives are suitable prodrugs. The term could be seen as a mere invitation to the skilled person to perform a research program in order to find the suitable variants, a situation, which imposes an undue burden on the skilled person (insufficient disclosure in the sense of Article 5 PCT) even when simple *in vivo* or *in vitro* tests are available to determine whether or not a particular compound is covered by the claims. Claim 1 has therefore been searched incompletely, omitting the term "prodrug".

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a

INTERNATIONAL SEARCH REPORT

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 03/01302

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 5508288	A	16-04-1996	AU 3641193 A EP 0630373 A1 WO 9318028 A1 JP 7504429 T MX 9301336 A1 ZA 9301713 A		05-10-1993 28-12-1994 16-09-1993 18-05-1995 01-10-1993 22-09-1994
US 4045439	A	30-08-1977	GB 1472766 A AU 8610175 A BE 835165 A1 DD 123339 A5 DE 2550179 A1 DK 500775 A FI 753113 A FR 2290209 A1 IN 141110 A1 JP 51070778 A NL 7512958 A NO 753718 A SE 7512447 A SE 7807225 A US 4085103 A ZA 7506710 A		04-05-1977 05-05-1977 30-04-1976 12-12-1976 13-05-1976 08-05-1976 08-05-1976 04-06-1976 22-01-1977 18-06-1976 11-05-1976 10-05-1976 10-05-1976 26-06-1978 18-04-1978 27-10-1976
DE 1157626	B		NONE		
DE 583207	C	30-08-1933	NL 34898 C US 2042023 A		26-05-1936
WO 9324458	A	09-12-1993	AU 4028393 A BG 99188 A BR 9306421 A CA 2134359 A1 CN 1080919 A EP 0642498 A1 FI 932423 A HR 930931 A1 HU 64303 A2 JP 7503737 T MX 9303100 A1 NO 944530 A OA 10114 A PL 299082 A1 SK 142694 A3 WO 9324458 A1 US 6001860 A		30-12-1993 28-07-1995 15-09-1998 09-12-1993 19-01-1994 15-03-1995 29-11-1993 30-06-1997 28-12-1993 20-04-1995 30-06-1994 25-11-1994 18-12-1996 05-04-1994 07-06-1995 09-12-1993 14-12-1999
WO 9414801	A	07-07-1994	WO 9414801 A1		07-07-1994
WO 0026203	A	11-05-2000	AU 1044700 A BR 9914868 A CA 2347060 A1 CN 1325390 T CZ 20011413 A3 WO 0026203 A1 EP 1124811 A1 HU 0104167 A2 JP 2002528538 T		22-05-2000 03-07-2001 11-05-2000 05-12-2001 12-09-2001 11-05-2000 22-08-2001 28-03-2002 03-09-2002

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/GB 03/01302

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0026203	A		NO 20012058 A PL 347506 A1 SK 4752001 A3	28-06-2001 08-04-2002 05-02-2002
DE 2502588	A	29-07-1976	DE 2502588 A1	29-07-1976
WO 0208221	A	31-01-2002	AU 8066701 A EP 1301484 A2 WO 0208221 A2 US 2002132853 A1	05-02-2002 16-04-2003 31-01-2002 19-09-2002
WO 03014064	A	20-02-2003	JP 2003055209 A WO 03014064 A1	26-02-2003 20-02-2003